rosiglitazone has been researched along with Obesity in 288 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 10 (3.47) | 18.2507 |
2000's | 162 (56.25) | 29.6817 |
2010's | 101 (35.07) | 24.3611 |
2020's | 15 (5.21) | 2.80 |
Authors | Studies |
---|---|
Brown, PJ; Henke, BR; Sternbach, DD; Willson, TM | 1 |
Chen, ML; Leng, Y; Shen, JH; Shen, Y; Tang, J; Xu, TF; Ye, YL; Yin, HZ; Zhou, Z; Zou, HJ | 1 |
Abad, MC; Askari, HB; De, D; Gaul, MD; Geisler, JG; Kasturi, J; Kemmerer, M; Kim, AJ; Lenhard, JM; Lin, L; Liu, J; O'Neill, JC; Patch, RJ; Player, MR; Rentzeperis, D; Searle, LL; Zhu, X | 1 |
Chen, J; Chen, L; Huang, L; Lai, H; Liang, X; Liu, J; Ma, L; Pei, H; Peng, A; Ran, Y; Sang, Y; Wei, Y; Xiang, M; Xie, C | 1 |
Fenaux, M; Halcomb, RL; Jones, CT; Romero, FA; Xu, Y | 1 |
Su, Y; Tang, L; Wang, T; Wang, W; Xiao, Q; Xie, M | 1 |
Ali, R; Allison, BA; Baker, C; Jonas, DE; LeBlanc, ES; Middleton, JC; Riley, S; Vander Schaaf, EB; Voisin, CE | 1 |
Kim, K; Roh, HC; So, J; Strobel, O; Taleb, S; Wann, J | 1 |
Blumberg, B; Chang, RC; Joloya, EM; Li, Z; Shioda, T; Shoucri, BM | 1 |
Amri, EZ; Balas, L; Batrow, PL; Bernoud-Hubac, N; Colson, C; Contu, L; Dieckmann, S; Durand, T; Fourmaux, B; Gautier, N; Klingenspor, M; Langin, D; Rochet, N; Roux, CH; Vigor, C | 1 |
Alexopoulos, SJ; Beretta, M; Byrne, FL; Cantley, J; Chen, SY; Garcia, CJ; Hoehn, KL; Larance, M; Olzomer, EM; Philp, A; Salamoun, JM; Santos, WL; Shah, DP; Smith, GC; Turner, N | 1 |
Appendino, G; Calzado, MA; Eugenia Prados, M; Ferreiro-Vera, C; Garrido-Rodriguez, M; Morrugares, R; Muñoz, E; Nadal, X; Palomares, B; Ruiz-Pino, F; Sánchez-Garrido, MA; Tena-Sempere, M; Vazquez, MJ; Velasco, I | 1 |
Duan, C; Hu, Y; Huang, W; Li, Y; Tan, J; Wang, Q | 1 |
Arya, S; Hansen, KR; Wild, RA | 1 |
Jacobs, C; Kumari, M; Lyubetskaya, A; Roh, HC; Rosen, ED; Taleb, S; Tenen, D; Tsai, LT | 1 |
Harashima, H; Hida, K; Hiradate, R; Khalil, IA; Matsuda, A; Sasaki, M | 1 |
Chen, R; Duan, F; Huang, S; Lin, T; Lv, J; Ma, H; Nie, L; Ren, L; Shan, W; Zhang, J | 1 |
Chen, MT; Gao, DD; Huang, JS; Li, YX; Wang, HY | 1 |
Cordoba-Chacon, J; Diaz-Ruiz, A; Kineman, RD; Lee, SM; Liew, CW; McCann, M; Muratalla, J; Remon-Ruiz, P | 1 |
Babin, PJ; Capilla, E; Gutiérrez, J; Lutfi, E; Navarro, I | 1 |
den Hartigh, LJ; Goodspeed, L; Houston, B; Turk, KE; Wang, S | 1 |
Gu, Z; Liu, Q; Qiang, L; Wang, J; Yu, J; Yu, S; Zhang, Y | 1 |
Beaudoin, MS; Foute-Nelong, J; Gaudio, N; Mutch, DM; Reed, JK; Wright, DC | 1 |
Guo, J; Li, L; Li, X; Wang, L; Wang, Y; Zhang, H; Zhong, T | 1 |
Mahboob, T; Tabassum, A | 1 |
Area-Gomez, E; Chan, M; Creusot, RJ; Fan, L; Fu, W; Ji, R; Kon, N; Kraakman, MJ; Larrea, D; Liu, Q; Namwanje, M; Postigo-Fernandez, J; Qiang, L | 1 |
Kuranaga, T; Ono, Y; Sato, Y; Takatsuki, S; Unno, Y; Wakimoto, T; Yamamoto, H; Yazawa, K | 1 |
Chen, J; Deng, S; Essandoh, K; Fan, GC; Gu, H; Holland, J; Huang, K; Jegga, AG; Li, Y; Liu, T; McNamara, RK; Mu, X; Nakamura, T; Peng, J; Peng, T; Perez-Tilve, D; Wang, B; Wang, X; Yates, E | 1 |
He, L; Kalugotla, G; Razani, B; Sauer, M; Schilling, JD; Tycksen, E; Weber, KJ | 1 |
Arteel, GE; Chartoumpekis, DV; Fazzari, M; Freeman, BA; Guimaraes, DA; Khoo, NKH; Li, L; Shiva, S | 1 |
Nemanich, S; Rani, S; Shoghi, K | 1 |
Rimbach, G; Schrader, E; Wein, S; Wolffram, S | 1 |
Chang, CJ; Liu, IM; Tzeng, TF | 1 |
Han, CT; Hartmann, L; Mayr, JA; Meierhofer, D; Sauer, S; Schroeder, FC; Weidner, C | 1 |
Arnould, T; Geeraert, B; Holvoet, P; Hulsmans, M; Tsatsanis, C | 1 |
Eckel, J; Flachs, P; Hensler, M; Horakova, O; Janovska, P; Jilkova, ZM; Kopecky, J; Medrikova, D; Rossmeisl, M; Sell, H | 1 |
Aryal, S; Candeloro, P; Decuzzi, P; Di Mascolo, D; Guindani, M; Hsueh, WA; J Lyon, C; Ramirez, MR; Wang, J | 1 |
Bravard, A; Disse, E; Laville, M; Rieusset, J; Tchernof, A; Veilleux, A; Vidal, H | 1 |
Burcelin, R; Campbell, M; Camps, M; Decaunes, P; Domingo, P; Escoté, X; Fernández-Real, JM; Frühbeck, G; Galitzky, J; Giralt, M; Kolditz, CI; Langin, D; Laville, M; Luche, E; Michalski, MC; Mingrone, G; Moreno-Navarrete, JM; Ortega, F; Pardo, G; Ricart, W; Rodriguez-Hermosa, JI; Sabater, M; Salvador, J; Serino, M; Vendrell, J; Vidal, H; Vidal-Puig, A; Viguerie, N; Villarroya, F; Waget, A; Xifra, G; Zorzano, A | 1 |
Burcelin, R; Fernández-Real, JM; Frühbeck, G; Luche, E; Mayas, D; Mingrone, G; Moreno-Navarrete, JM; Ortega, FJ; Ricart, W; Rodriguez-Hermosa, JI; Serino, M; Tinahones, FJ | 1 |
Droog, S; Havekes, LM; Maas, AC; Offerman, EH; Pieterman, EJ; Princen, HM; van den Hoek, AM; van den Hoogen, RM; van der Hoorn, JW; van Nieuwkoop, A | 1 |
Aragonès, G; Beltrán-Debón, R; Camps, J; García-Heredia, A; Geeraert, B; Holvoet, P; Joven, J; Pedro-Botet, J; Rodríguez-Gallego, E; Rull, A | 1 |
Fan, N; Hou, Y; Liu, R; Peng, L; Peng, Y; Shen, W; Sun, H; Wang, Y; Xia, Z; Zhang, L | 1 |
Sun, XD; Yu, YR | 1 |
Cabay, RJ; Castellanos, KJ; Fantuzzi, G; Malecki, EA | 1 |
Narasimhan, S; Weinstock, RS | 1 |
Emmett, N; Leander, M; Li, L; Wang, G; Zhang, Y; Zhao, X | 1 |
Alméras, N; Anand, SS; Dagenais, GR; Després, JP; Gerstein, HC; Hunt, DL; Jung, H; Punthakee, Z; Sharma, AM; Yusuf, S | 1 |
Meierhofer, D; Sauer, S; Weidner, C | 1 |
Ciaraldi, TP; Samad, F; Wang, J | 1 |
Cao, Q; Chai, J; Guo, F; Ma, J; Zhang, M; Zhang, Y; Zhao, R; Zhao, W; Zhou, B | 1 |
Chattipakorn, N; Chattipakorn, SC; Pipatpiboon, N; Sripetchwandee, J | 1 |
Badgeley, MA; Bagalkot, V; Deiuliis, JA; Kampfrath, T; Maiseyeu, A; Rajagopalan, S | 1 |
Beckett, E; Cardoso, RC; Chazenbalk, G; Dumesic, D; Keller, E; Madrigal, V; Moeller, J; Padmanabhan, V; Pease, A; Veiga-Lopez, A | 1 |
Albu, J; Chiu, YL; Christos, P; Donovan, DS; Engelson, ES; Ginsberg, HN; Glesby, MJ; Ham, K; Hammad, H; Kotler, DP; Leung, V; Zhu, YS | 1 |
Pugalendi, KV; Radhiga, T; Sundaresan, A | 1 |
Farokhzad, OC; Langer, R; Xu, X; Xue, Y; Zhang, XQ | 1 |
Guo, DF; Liu, X; Lu, KT; Mukohda, M; Rahmouni, K; Sigmund, CD; Stump, M | 1 |
Gu, H; Hinds, TD; Khuder, SS; Lecka-Czernik, B; Najjar, SM; Qiu, B; Russo, L; Sanchez, ER; Stechschulte, LA; Warrier, M; Xu, Y; Yong, W; Zhang, M | 1 |
Franczyk, MP; Imai, S; Kelly, SC; Moseley, AC; Qi, N; Stromsdorfer, KL; Yamaguchi, S; Yoon, MJ; Yoshino, J | 1 |
Asuncion, F; Boyce, R; Chen, MM; Chinookoswong, N; Dwyer, D; Han, CY; Ke, HZ; Li, X; Liu, B; Niu, QT; Ominsky, MS; Stanislaus, S; Stolina, M; Véniant, MM; Villasenor, K; Wang, J; Wong, P; Xu, J | 1 |
Kleemann, R; Kooistra, T; Liang, W; Morrison, MC; Mulder, P; van Bockel, JH; Verschuren, L; Wielinga, PY | 1 |
Andreu, I; Buchwalder, C; Gray, SL; Häfeli, UO; Leung, D; Nicholson, KE; Saatchi, K; Schmitt, V; Tod, SE | 1 |
Andres, A; Badger, TM; Blackburn, ML; Chen, JR; Frye, RE; Lazarenko, OP; Rose, S; Shankar, K | 1 |
Soni, H | 1 |
Guo, M; Lei, Y; Li, C; Lu, XY; Xu, S; Zhao, D | 1 |
Frank, S; Goren, I; Pfeilschifter, J; Siebert, A | 1 |
Brunt, JJ; Cai, EP; Krishnamurthy, M; Luk, CT; Schroer, SA; Shi, SY; Sivasubramaniyam, T; Winer, DA; Woo, M | 1 |
Benson, KK; Briggs, ER; Chen, ER; Damle, M; Dispirito, JR; Dzeng, RK; Emmett, MJ; Foong, YH; Jolivert, JF; Kissig, M; Lazar, MA; Li, Z; Lim, HW; Medina, CJ; Mullican, SE; Peed, LC; Rajapurkar, SR; Seale, P; Soccio, RE; Steger, DJ; Won, KJ | 1 |
Gottlieb, RA; Taylor, D | 1 |
Burkart, A; Chawla, A; Chouinard, M; Corvera, S; Czech, MP; Konda, S; Lin, C; Nicoloro, SM; Perugini, RA; Puri, V; Ranjit, S; Straubhaar, J | 1 |
Duval, C; Kersten, S; Keshtkar, S; Müller, M; Stienstra, R; van der Laak, J | 1 |
Choi, JW; Kim, AY; Kim, JB; Kim, M; Lee, YS; Masuzaki, H; Park, KS; Son, HJ; Yasue, S | 1 |
Huang, W; Huang, XZ; Yu, RM; Zhu, HL | 1 |
Ecelbarger, CM; Liu, H; Ressom, HW; Song, J; Tiwari, S | 1 |
Burkart, A; Chouinard, M; Corvera, S; Gealekman, O; Nicoloro, SM; Straubhaar, J | 1 |
Chalasani, N; Vuppalanchi, R | 1 |
Brunani, A; Castagna, G; Gondoni, LA; Graci, S; Liuzzi, A; Titon, A; Viberti, GC | 1 |
Behar, A; Charnaux, N; Cohen-Boulakia, F; Cosson, E; Dabiré, H; Léger, G; Lestrade, R; Tarhzaoui, K; Valensi, P | 1 |
Cohen, P | 1 |
Ecelbarger, CM; Hu, J; Hu, X; Riazi, S; Tiwari, S; Wang, X | 1 |
Arroyo, V; Clària, J; Dong, B; Ferré, N; González-Périz, A; Gronert, K; Horrillo, R; López-Parra, M; Martínez-Clemente, M; Morán-Salvador, E; Titos, E | 1 |
Barbosa Aguila, M; de Souza Mendonca, L; Evangelista Carneiro, R; Fernandes-Santos, C; Mandarim-de-Lacerda, CA | 1 |
Berger, JP; Berthiaume, M; Deshaies, Y; Festuccia, WT; Laplante, M; Thieringer, R | 1 |
Cheon, HG; Choi, BH; Do, MS; Kim, YH | 1 |
Rechler, MM; Zappalà, G | 1 |
Gu, J; Li, C; Li, Y; Meng, D; Miao, Z; Wang, B; Wang, CY; Wang, J; Wang, L; Xing, X; Yan, S; Yuan, Y; Zhang, S | 1 |
Annicotte, JS; Chavey, C; Clapé, C; Fajas, L; Guma, A; Hotamisligil, GS; Iankova, I; Jardin-Watelet, B; Lagarrigue, S; Langin, D; Lazennec, G; Mataki, C; Renard, E; Sanches, R; Schmidt, J; Stich, V; Strieter, R; Teyssier, J; Tuthill, A; Vidal-Puig, A; Vitkova, M; Yamamoto, H; Zorzano, A | 1 |
Andres, J; Biedasek, K; Bobbert, T; Clemenz, M; Kintscher, U; Mai, K; Meinus, S; Möhlig, M; Pfeiffer, AF; Reinecke, F; Sabath, M; Spranger, J; Spuler, S; Weicht, J; Weickert, MO | 1 |
Cai, B; Chen, L; Pan, Y; Wang, K; Wang, S; Xu, B; Yu, X; Zhou, S | 1 |
Brûlé, S; Chewchuk, S; Houde, V; Lavigne, C; Liu, Y; Marette, A; Pilon, G; Sweeney, G; Xu, A | 1 |
Ahmed, M; Edelmann, MJ; Karpe, F; Kessler, BM; Neville, MJ | 1 |
Hong, JH; Hwang, EY; Jeong, YJ; Kim, HJ; Lee, IS | 1 |
Cipriani, S; Fiorucci, S; Mencarelli, A; Palladino, G | 1 |
Blüher, M; Catalán, V; Fernández-Real, JM; Frühbeck, G; Gómez-Ambrosi, J; Martínez-Barricarte, R; Moreno-Navarrete, JM; Ortega, FJ; Ricart, W; Rodríguez de Cordoba, S; Sabater, M | 1 |
Bak, EJ; Cha, JH; Kim, JM; Park, HG; Yoo, YJ | 1 |
Calmes, JM; Darimont, C; Gaillard, RC; Giusti, V; Leyvraz, C; Paroz, A; Pralong, FP; Suter, M; Verdumo, C | 1 |
Bahia, LR; Bouskela, E; Domingues, RC; Geloneze, B; Godoy-Matos, AF; Kraemer-Aguiar, LG; Tambascia, M | 1 |
Artis, DR; Bollag, G; Erbe, DV; Gareski, T; Gartrell, K; Harding, K; Ibrahim, PN; Jalenak, M; Kubasiak, D; Lin, JJ; Mansour, TS; Panza, D; Perreault, M; Saiah, E; Tobin, JF; Vlasuk, GP; Wang, S; Will, S; Womack, P | 1 |
Bassaganya-Riera, J; Guri, AJ; Hontecillas, R | 1 |
Benomar, Y; Bouchaert, E; Casteilla, L; Dacquet, C; Dumont, J; Guédin, A; Hennuyer, N; Ktorza, A; Langlois, A; Lefebvre, B; Lefebvre, P; Pattou, F; Pénicaud, L; Staels, B | 1 |
Allen, K; Cali, AM; Caprio, S; Pierpont, BM; Savoye, M; Shaw, MM; Taksali, SE | 1 |
Chaudhuri, A; Dandona, P; Ghanim, H | 1 |
Döbrönte, R; Drimba, L; Németh, J; Pázmány, T; Peitl, B; Sári, R; Szilvássy, Z; Varga, A | 1 |
Auwerx, J; Houtkooper, RH | 1 |
Banks, AS; Blüher, M; Boström, P; Chalmers, MJ; Choi, JH; Estall, JL; Griffin, PR; Kajimura, S; Kamenecka, TM; Laznik, D; Ruas, JL; Spiegelman, BM | 1 |
Bekiari, E; Kaloyianni, M; Koliakos, G; Paletas, K; Sarigianni, M; Topouridou, K; Tsapas, A | 1 |
Chen, YT; Cheng, JT; Chi, TC; Lee, HH; Lo, SH; Yeh, CH | 1 |
Clemenz, M; Foryst-Ludwig, A; Hartge, M; Hess, K; Kintscher, U; Marx, N; Sprang, C; Unger, T | 1 |
Bu, SY; Chen, X; Guo, H; Hannaford, J; Jin, D; Mashek, DG; Zhang, Y | 1 |
Al-Jebawi, AF | 1 |
Liu, Q; Niu, YJ; Tao, RY; Tian, JY; Ye, F; Zhu, HB; Zhu, P | 1 |
Almeida, RL; Almeida, TS; Fedrizzi, D; Fedrizzi, P | 1 |
Kahn, BB; McGraw, TE | 1 |
Baek, MC; Hwang, HH; Kim, JG; Lee, JE; Lee, W; Moon, PG; Ryu, SH | 1 |
Rabøl, R | 1 |
Bandyopadhyay, G; Fan, W; Gayen, JR; Li, P; Lu, M; Mahata, SK; Nalbandian, S; Olefsky, JM; Sarruf, DA; Schwartz, MW; Sharma, S; Talukdar, S; Webster, NJ | 1 |
Choi, WS; Kim, IS; Kim, Y; Lee, JJ; Myung, CS; Zhang, WY | 1 |
Li, D; Li, X; Li, Y; Ming, J; Shi, Y; Xie, Y; Zhang, N | 1 |
Bastacky, S; Bilan, VP; Jones, HB; Mayers, RM; Poucher, SM; Salah, EM; Tofovic, SP; Zinker, B | 1 |
Hu, W; Qiao, J | 1 |
Llorens, S; Mendizábal, Y; Nava, E | 1 |
Fernández-Real, JM; Moreno-Navarrete, JM; Ortega, F; Peral, B; Pérez-Pérez, R; Ricart, W; Sabater, M; Serrano, M; Tinahones, F | 1 |
Banks, AS; Bruning, JB; Busby, SA; Cameron, MD; Chalmers, MJ; Choi, JH; Griffin, PR; He, Y; Jurczak, MJ; Kamenecka, TM; Kumar, N; Kuruvilla, DS; Laznik, D; Marciano, DP; Schürer, SC; Shin, Y; Shulman, GI; Spiegelman, BM; Vidović, D | 1 |
Mohsen, IA | 1 |
Gierman, LM; Huizinga, TW; Kleemann, R; Kloppenburg, M; Kooistra, T; Koudijs, A; Stojanovic-Susulic, V; Stoop, R; van der Ham, F; van Osch, GJ; Wielinga, PY; Zuurmond, AM | 1 |
Bardova, K; Flachs, P; Illig, T; Janovska, P; Jilkova, ZM; Kopecky, J; Kuda, O; Kus, V; Rossmeisl, M; Svobodova, M; Wang-Sattler, R; Yu, Z | 1 |
Guo, XH; Hui, Y; Yuan, GH; Zhang, WY | 1 |
Ailhaud, G; Amri, EZ; Døskeland, SO; Jia, B; Kopperud, R; Kristiansen, K; Ma, T; Madsen, L; Petersen, RK; Techer, N; Wang, J | 1 |
Balguy, I; Benelli, C; Cadoudal, T; Distel, E; Durant, S; Penot, G | 1 |
Chambers, KT; Chen, Z; Colca, JR; Finck, BN; Hall, AM; Kletzien, RF; McDonald, WG; Mitra, MS; Qi, N; Vigueira, PA | 1 |
Jang, JE; Jeon, MJ; Kim, EH; Kim, HS; Kim, M; Ko, MS; Koh, EH; Lee, CH; Lee, KU; Leem, J; Park, HS; Park, IS; Yoo, HJ | 1 |
Brooks, VL; McCully, BH; Zhao, D | 1 |
Adamski, J; Bardova, K; Bunschoten, A; Flachs, P; Hensler, M; Horakova, O; Illig, T; Janovska, P; Keijer, J; Kopecky, J; Kuda, O; Kus, V; Medrikova, D; Prehn, C; Rossmeisl, M; van Schothorst, EM; Wang-Sattler, R | 1 |
Jang, JS; Jeong, JC; Kim, EJ; Lee, SJ; Park, UH; Sung, MR; Um, SJ; Youn, H | 1 |
Bland, JS; Darland, G; Havekes, LM; Konda, V; Romijn, JA; Tripp, ML; van den Berg, SA; van Diepen, JA; van Dijk, KW; Voshol, PJ; Vroegrijk, IO | 1 |
Bigley, AL; Jones, HB; Pemberton, J; Randall, KJ | 1 |
Ensor, J; Esteva, FJ; Gonzalez-Angulo, AM; Green, MC; Hortobagyi, GN; Koenig, KB; Lee, MH; Moulder, SL; Murray, JL; Yeung, SC | 1 |
Cherian-Shaw, M; Hammock, BD; Hye Khan, MA; Imig, JD; Nagasawa, T; Shaw, SM; Walsh, KA | 1 |
Koc, M; Kovácová, Z; Kracmerová, J; Langin, D; Malisová, L; Rossmeislová, L; Siklová-Vítková, M; Stich, V; Tencerová, M; Viquerie, N | 1 |
Berger, J; Dallas-Yang, Q; Doebber, T; Jiang, G; Li, Z; Liu, F; Moller, DE; Shen, X; Szalkowski, D; Wu, M; Zhang, BB; Zhou, G | 1 |
Häring, HU; Stumvoll, M | 1 |
Aleksunes, LM; Reagan, LA; Vergara, CM; Wang, F | 1 |
Banday, AA; Hussain, T; Lokhandwala, MF; Umrani, DN | 1 |
Belz, U; Herling, AW; Juretschke, HP; Kalisch, J; Kleinschmidt, E; Kramer, W; Kuhlmann, J; Neumann-Haefelin, C; Stein, M | 1 |
Anglard, P; Bonnafous, S; Chavey, C; Mari, B; Monthouel, MN; Tartare-Deckert, S; Van Obberghen, E | 1 |
Cobitz, AR; Haimbach, RE; Jucker, BM; Mayer, ME; Ohlstein, DH; Sarkar, SK; Schaeffer, TR; Smith, SA | 1 |
Viberti, GC | 1 |
Fischer, S; Hanefeld, M | 1 |
Jones, NP; Jones, TA; Sautter, M; Van Gaal, LF | 1 |
Birmingham, J; Buckingham, RE; Changani, KK; Hockings, PD; O'Brien, P; Osborne, J; Reid, DG; Saeed, N; Toseland, CN | 1 |
Cawthorne, MA; Converset, V; Heller, M; Hochstrasser, DF; Nolan, A; Sanchez, JC; Schmid, G; Sennitt, MV; Wang, S | 1 |
Kim, HS; Kim, MS; Koh, EH; Lee, KU; Park, HS; Park, JY; Youn, JH; Youn, JY | 1 |
Chilton, RJ; Stolar, MW | 1 |
Beck-Nielsen, H; Henriksen, JE; Hother-Nielsen, O; Poulsen, MK | 1 |
Barnes, GT; Chen, H; Chou, CJ; Nichols, A; Ross, JS; Sole, J; Tan, G; Tartaglia, LA; Xu, H; Yang, D; Yang, Q | 1 |
Marescaux, J; Rubino, F | 1 |
Lokhandwala, M; Marwaha, A; Trivedi, M | 1 |
Haslbeck, M; Jakob, S; Kellerer, M; Linn, T | 1 |
Bains, RK; Fairhall, KM; Flavell, DM; Le Tissier, P; Robinson, IC; Strom, M; Wells, SE | 1 |
Béréziat, V; Burnol, AF; Capitaine, N; Cariou, B; Girard, J; Kergoat, M; Laville, M; Le Marcis, V; Vega, N; Vidal, H | 1 |
Akbay, E; Aktürk, M; Arslan, M; Ayvaz, G; Cakir, N; Elbeg, S; Karakoç, A; Sancak, B; Taneri, F; Törüner, F | 1 |
Péterfy, M; Phan, J; Reue, K | 1 |
Al-Haddad, W; Aljada, A; Dandona, P; Dhindsa, S; Ghanim, H; Hofmeyer, D; Mohanty, P; Syed, T; Tripathy, D | 1 |
Bacon, BR; Brunt, EM; Neuschwander-Tetri, BA; Oliver, D; Wehmeier, KR | 1 |
Febbraio, MA; Hawley, JA; Lau, W; Lessard, SJ; Lo Giudice, SL; Reid, JJ; Turner, N; Watt, MJ | 1 |
Dufour, JF; Oneta, CM | 1 |
Nagamani, M; Sepilian, V | 1 |
Chouinard, M; Chui, PC; Corvera, S; Czech, MP; Lazar, MA; Leszyk, J; Nicoloro, S; Straubhaar, J; Wilson-Fritch, L | 1 |
Füchtenbusch, M; Löbner, K | 1 |
Brunani, A; Caumo, A; Graci, S; Liuzzi, A; Margarini, C; Viberti, GC | 1 |
Banz, WJ; Davis, J; Iqbal, MJ; Peterson, R | 1 |
Hanefeld, M | 1 |
Arch, JR; Augstein, P; Cawthorne, MA; Demuth, HU; Heinke, P; Hoffmann, T; Meyer, A; Sennitt, MV; Stocker, C; Subramanian, A; Wargent, E | 1 |
Chen, YY; Li, CM; Li, GW; Li, H; Liu, KL; Tang, YL; Wang, JP; Xing, XY; Yang, WY | 1 |
Bonen, A; Coort, SL; Coumans, WA; Glatz, JF; Luiken, JJ; van der Vusse, GJ | 1 |
Barkhem, T; Beno, DW; Cherrington, A; Edgerton, DS; Efendic, S; Fey, T; Fung, S; Goos-Nilsson, A; Grynfarb, M; Jacobson, PB; Kym, PR; Lane, BC; Link, JT; Marsh, K; Mika, A; Nga-Nguyen, B; Nguyen, PT; Ohman, L; Opgenorth, TJ; Osterland, M; Tu, N; von Geldern, TW; Wang, J; Wilcox, D; Zinker, B | 1 |
Carvalheira, JB; Carvalho-Filho, MA; Curi, R; de Oliveira, MG; Hirabara, SM; Saad, MJ; Seabra, AB; Ueno, M; Velloso, LA | 1 |
Lokhandwala, MF; Trivedi, M | 1 |
Ecelbarger, CA; Hu, X; Khan, O; Riazi, S; Song, J; Wade, JB | 1 |
Chetty, R; Coppack, S; Harte, A; Katz, J; Kumar, S; McTernan, P; Smith, S | 1 |
Campbell, IW | 1 |
James, AP; Mamo, JC; Watts, GF | 1 |
Raskin, P; Strowig, SM | 1 |
Aljada, A; Dandona, P; Dhindsa, S; Ghanim, H; Ravishankar, S; Sanalkumar, N; Tripathy, D | 1 |
Moreno Sánchez, D | 1 |
Cantürk, Z; Cetinarslan, B; Komsuoglu, B; Sahin, T; Tarkun, I; Türemen, E | 1 |
Graham, TE; Kahn, BB; Kotani, K; Mody, N; Peroni, OD; Preitner, F; Quadro, L; Yang, Q; Zabolotny, JM | 1 |
Abbasi, F; Chu, JW; Kim, SH; Lamendola, C; McLaughlin, TL; Polonsky, KS; Reaven, GM | 1 |
Chen, ZP; Febbraio, MA; Hashem, M; Hawley, JA; Kemp, BE; Lessard, SJ; Reid, JJ; Watt, MJ | 1 |
Déchêne, F; Dodin, S; Forest, JC; Lemay, A; Turcot, L | 1 |
Andrew, R; Livingstone, DE; McInnes, KJ; Walker, BR | 1 |
Kjølhede, P; Nystrom, FH; Sauma, L; Söderström, M; Stenkula, KG; Strålfors, P | 1 |
Leiter, EH; Mistry, J; Pan, HJ; Reifsnyder, PC; Xiao, Q; Zhang, W | 1 |
Bullock, M; Cook, C; Gaillard, T; Kaplow, J; Osei, K; Schuster, D | 1 |
Ardecky, RJ; Boehm, MF; Broderick, CL; Carfagna, MA; Crombie, DL; D'Arrigo, J; Etgen, GJ; Faul, MM; Grese, TA; Havel, H; Hein, NI; Heyman, RA; Jolley, D; Klausing, K; Leibowitz, MD; Liu, S; Mais, DE; Mapes, CM; Marschke, KB; Michellys, PY; Montrose-Rafizadeh, C; Ogilvie, KM; Pascual, B; Reifel-Miller, A; Rungta, D; Tyhonas, JS; Urcan, MS; Wardlow, M; Yumibe, N | 1 |
Hada, Y; Ito, Y; Kadowaki, T; Maki, T; Takekawa, S; Tsuchida, A; Yamauchi, T | 1 |
Adler, S; Banz, WJ; Davis, J; Henry, N; Higginbotham, DA; Hou, Y; Meyers, CY; Oitker, J; Peterson, R; Steinle, JJ; Winters, TA | 1 |
Biller, S; Cap, M; Chen, S; Cheng, PT; Chu, C; Devasthale, P; Farrelly, D; Fenderson, W; Gregg, R; Gu, L; Hariharan, N; Harrity, T; Jeon, Y; Kunselman, L; Mookhtiar, KA; Ponticiello, R; Qu, F; Ren, J; Ryono, D; Seethala, R; Shao, C; Tieman, A; Wang, W; Wetterau, J; Yang, WP; Zhang, H; Zhou, M | 1 |
Blaak, EE; Hesselink, MK; Mensink, M; Moonen-Kornips, E; Russell, AP; Schaart, G; Schrauwen, P; Sels, JP | 1 |
Arslan, M; Ayvaz, G; Bingöl, B; Biri, A; Cakir, N; Karakoç, A; Tiras, B; Törüner, F; Yilmaz, M | 1 |
Rennings, AJ; Smits, P; Stewart, MW; Tack, CJ | 1 |
Orchard, TJ | 1 |
Esposito, K; Giugliano, D | 1 |
Brandlhofer, S; Dorfmeister, B; Fürnsinn, C; Hagerty, BP; Hermann, M; Patsch, W; Schaap, FG; Stangl, H; Strobl, W | 1 |
Andreelli, F; Beauloye, C; Bertrand, L; Foretz, M; Guigas, B; Horman, S; Taleux, N; Viollet, B | 1 |
Houstis, N; Lander, ES; Rosen, ED | 1 |
Aiello, LP; Clermont, A; Della Vecchia, K; King, GL; Kondo, T; Mastumoto, M; Rask-Madsen, C; Sotiropoulos, KB; Takahashi, J; Yasuda, Y | 1 |
Aramori, I; Fujimura, T; Kimura, C; Mutoh, S; Oe, T; Sakuma, H; Takata, Y | 1 |
Kurosaki, E; Maruyama, T; Nakano, R; Shibasaki, M; Shimaya, A; Yokono, M; Yoshida, S | 1 |
Fried, SK; Goldberg, AP; Goldberg, NH; Gong, DW; Horenstein, RB; Hu, H; Hull, K; Lee, MJ; Nicklas, BJ; Pollin, TI; Ryan, AS; Shuldiner, AR; Snitker, S; Yang, RZ | 1 |
Chen, YT; Li, PP; Liu, Q; Lu, XP; Ning, ZQ; Shan, S; Shen, ZF; Sun, SJ; Xie, MZ | 1 |
Ecelbarger, CA; Hu, X; Khan, O; Riazi, S; Tiwari, S | 1 |
Erbe, DV; Gartrell, K; Kirincich, SJ; Perreault, M; Suri, V; Tobin, JF; Wang, S; Will, S; Zhang, YL | 1 |
Bagust, A; Beale, S; Hulme, L; Martin, A; Shearer, AT | 1 |
Bagust, A; Goertz, A; Liebl, A; Schoeffski, O; Shearer, AT | 1 |
Ampudia-Blasco, FJ; Bagust, A; Martínez-Lage Alvarez, B; París, G; Pérez Escolano, I; Shearer, AT | 1 |
Aljada, A; Chaudhuri, A; Dandona, P; Dhindsa, S; Ghanim, H; Viswanathan, P | 1 |
Bandyopadhyay, GK; Ofrecio, J; Olefsky, JM; Yu, JG | 1 |
Ishida, Y; Ito, M; Kakutani, M; Matsushita, M; Nishiu, J; Shibata, T; Shindo, M | 1 |
Bellot-Rojas, P; Caracas-Portilla, N; Cardoso-Saldaña, G; Jurado-Santacruz, F; Posadas-Romero, C; Posadas-Sanchez, R; Zamora-Gonzalez, J | 1 |
Chow, WS; Hoo, RL; Kraegen, EW; Lam, KS; Sweeney, G; Tso, AW; Wang, Y; Wat, NM; Xu, A; Xu, JY; Zhang, J | 1 |
Morin-Papunen, LC; Rautio, K; Ruokonen, A; Tapanainen, JS | 1 |
Franck, N; Kjølhede, P; Nystrom, FH; Paulsson, JF; Sauma, L; Söderström, M; Strålfors, P; Westermark, GT | 1 |
Hu, FB; van Dam, RM | 1 |
Hesselink, MK; Mensink, M; Russell, AP; Schaart, G; Schrauwen, P; Sels, JP | 1 |
Belury, MA; Liu, LF; Purushotham, A; Wendel, AA | 1 |
Andrew, R; Homer, NZ; Karpe, F; Stimson, RH; Tan, GD; Wake, DJ; Walker, BR | 1 |
Adler, S; Banz, W; Cho, KW; Davis, J; Higginbotham, A; Kim, YC; Moustaid-Moussa, N; O'Connor, T; Peterson, R; Shay, N; Tebbe, A | 1 |
Hirosumi, J; Kawamura, I; Kimura, C; Manda, T; Minoura, H; Mutoh, S; Seki, J; Takakura, S; Takeshita, S | 1 |
Brunani, A; Castagna, G; Caumo, A; Graci, S; Liuzzi, A; Viberti, G | 1 |
Beaser, RS; Levy, P | 1 |
Asano, S; Hansen, MK; Higashiyama, H; Mattie, MD; Okamoto, Y; Qiu, Y; Rong, JX; Ryan, TE; Strum, JC; Xie, M; Zhang, V; Zhu, L | 1 |
Alevizos, M; Angelopoulou, N; Iliadis, F; Kadoglou, NP; Liapis, CD; Perrea, D | 1 |
Bernante, P; Bianchi, K; Calcagno, A; Federspil, G; Milan, G; Pagano, C; Pilon, C; Rizzuto, R; Rossato, M; Urbanet, R; Vettor, R | 1 |
Jeon, MJ; Kim, M; Kim, MS; Kim, SW; Kim, SY; Koh, EH; Lee, KU; Park, HS; Park, IS; Park, JY; Ryu, JW; Youn, JH | 1 |
Henry, MJ; Nicholson, GC; Pasco, JA | 1 |
Bohdanowicz-Pawlak, A; Jakubowska, J; Milewicz, A | 1 |
Hart, CM; Holguin, F; Rojas, M | 1 |
Chan, L; Chow, WS; Fong, CH; Hoo, RL; Lam, KS; Tam, S; Tse, HF; Tso, AW; Xu, A; Yau, MH | 1 |
Comarow, A | 1 |
Anhalt, H; Bhangoo, A; Collin, GB; Maclaren, N; Marshall, JD; Naggert, JK; Sinha, SK; Ten, S | 1 |
Bahia, LR; Bottino, DA; Bouskela, E; Kraemer de Aguiar, LG; Nivoit, P; Villela, NR | 1 |
Donaldson, J; Garcia-Puig, J; Hamann, A; Paul, G; Stewart, M | 1 |
Best, JD; Fairley, KF; Farish, S; Kincaid-Smith, P; Proietto, J | 1 |
Briscoe, CP; Buckingham, RE; Clapham, JC; Moore, GB; Pickavance, LC; Wilding, JP | 1 |
Bennett, BD; Minge, CE; Norman, RJ; Robker, RL | 1 |
Abram, SR; Carter, C; Dearman, J; Hester, RL; Xiang, L | 1 |
Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, E; Gravina, A; Maffioli, P; Piccinni, MN; Ragonesi, PD; Salvadeo, SA | 1 |
Atabek, ME | 1 |
Cong, WN; Liu, GT; Tao, RY; Tian, JY; Ye, F | 1 |
Bellmann, K; Centeno-Baez, C; Dallaire, P; Deshaies, Y; Gélinas, S; Lamontagne, J; Laplante, M; Latour, MG; Marette, A; Penfornis, P; Peyot, ML; Prentki, M; Scherer, PE; Trujillo, ME | 1 |
Benavides, S; Romo, A | 1 |
Kadowaki, T; Kubota, N; Takasawa, K; Terauchi, Y | 1 |
Kallen, CB; Lazar, MA | 1 |
Boam, DS; Dickson, AJ; Sidaway, JE; Smith, SA | 1 |
Bischoff, ED; Boehm, MF; Cesario, RM; Crombie, DL; Davies, PJ; Hamann, LG; Heyman, RA; Jow, L; Mondon, CE; Mukherjee, R; Nadzan, AM; Paterniti, JR | 1 |
Akatsuka, H; Arakawa, K; Homma, K; Iijima, I; Inamasu, M; Kawanami, S; Matsumoto, M; Okumura, K; Ozeki, M; Saiga, Y; Watanabe, A; Yasuda, K | 1 |
Al-Barazanji, KA; Bond, B; Buckingham, RE; Clapham, JC; Connor, SC; Slaughter, M; Toseland, CD; Turner, NC; West, A | 1 |
Akanuma, Y; Ide, T; Kadowaki, T; Mochizuki, T; Murakami, K; Ohashi, M; Tobe, K; Yazaki, Y | 1 |
Buckingham, RE; Chattington, PD; Walker, AB; Williams, G | 1 |
Alexandersson, M; Bamberg, K; Bergström, M; Dahllöf, B; Edvardsson, U; Ljung, B | 1 |
Auwerx, J; Rieusset, J; Vidal, H | 1 |
Buckingham, RE; Pickavance, LC; Tadayyon, M; Widdowson, PS; Wilding, JP | 1 |
Arch, JR; Buckingham, RE; Cai, XJ; Lister, CA; Pickavance, L; Wilding, J; Williams, G; Wilson, S | 1 |
Chapman, H; Gould, GW; Lister, CA; Maier, VH; Melvin, DR; Murphy, GJ | 1 |
Cawthorne, MA; Crombie, DL; Heyman, RA; Hislop, DC; Liu, YL; Sennitt, MV | 1 |
Kenyon, CJ; Livingstone, DE; Walker, BR | 1 |
Cawthorne, MA; Emilsson, V; Heyman, R; Liu, YL; O'Dowd, J; Sennitt, M; Wang, S | 1 |
Daubresse, JC | 1 |
Ahima, RS; Bailey, ST; Banerjee, RR; Bhat, S; Brown, EJ; Lazar, MA; Patel, HR; Steppan, CM; Wright, CM | 1 |
Boehm, M; Crombie, DL; Davies, PJ; Depre, C; Heyman, RA; Leibowitz, MD; Liu, S; Nagy, L; Singh Ahuja, H; Tontonoz, P | 1 |
Buckingham, RE; Finegood, DT; Kojwang, D; Leonard, T; McArthur, MD; Thomas, MJ; Topp, BG | 1 |
Jacinto, SM; Ljung, B; Oakes, ND; Thalén, PG | 1 |
Brown, KK; Görgün, CZ; Harrington, WW; Hotamisligil, GS; Kliewer, SA; Oliver, WR; Tong, Q; Uysal, KT; Way, JM; Willson, TM | 1 |
Buckingham, RE; Pickavance, LC; Wilding, JP | 1 |
Atzpodien, E; Bedoucha, M; Boelsterli, UA | 1 |
Akanuma, Y; Ezaki, O; Fukayama, M; Hori, W; Ide, T; Itai, A; Kadowaki, T; Kagechika, H; Kamon, J; Kato, S; Kimura, S; Komeda, K; Kubota, N; Miki, H; Motojima, K; Murakami, K; Nagai, R; Shudo, K; Terauchi, Y; Tobe, K; Tsuboyama-Kasaoka, N; Tsuchida, A; Waki, H; Yamauchi, N; Yamauchi, T | 1 |
Adler, A; Bush, E; Kramer, D; Rondinone, CM; Shapiro, R | 1 |
Brunmair, B; Fürnsinn, C; Gras, F; Nowotny, P; Roden, M; Vierhapper, H; Waldhäusl, W | 1 |
Buckingham, RE; Clarke, K; Cole, MA; Desrois, M; Draper, NJ; Sidell, RJ | 1 |
Arner, P; Dicker, A; Hauner, H; Lönnqvist, F; Näslund, E; Rydén, M; van Harmelen, V | 1 |
Chun, D; Cobitz, AR; Davis, HM; Haimbach, RE; Jucker, BM; Mayer, M; McIntosh, TS; Ohlstein, DH; Sarkar, SK; Schaeffer, TR; Smith, SA | 1 |
Akarca, C; Barton, DM; Baskar, V; Buch, HN; Kamalakannan, D; Singh, BM | 1 |
Anderson, JW; Frederich, RC; Konz, EC; Reynolds, LR | 1 |
21 review(s) available for rosiglitazone and Obesity
Article | Year |
---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligands; Models, Molecular; Neoplasms; Nuclear Proteins; Obesity; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2000 |
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
Topics: Animals; Anticholesteremic Agents; Drug Delivery Systems; Drug Development; Humans; Hypoglycemic Agents; Lipid Metabolism; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; PPAR gamma; Protein Structure, Tertiary | 2020 |
Screening for Prediabetes and Type 2 Diabetes in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Topics: Adolescent; Advisory Committees; Child; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Mass Screening; Metformin; Obesity; Prediabetic State; Preventive Health Services; Randomized Controlled Trials as Topic; Rosiglitazone | 2022 |
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.
Topics: Bariatric Surgery; Biomarkers; Biopsy; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Exercise; Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Cirrhosis; Liver Diseases; Metabolic Syndrome; Metformin; Obesity; Oxidative Stress; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Weight Loss | 2009 |
Mitochondrial function in skeletal muscle in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Electron Transport; Humans; Hyperglycemia; Hypoglycemic Agents; Life Style; Mitochondria; Muscle Fibers, Skeletal; Muscle, Skeletal; Obesity; Oxidative Stress; Oxygen Consumption; Rosiglitazone; Saponins; Thiazolidinediones | 2011 |
Glitazones: clinical effects and molecular mechanisms.
Topics: Adipose Tissue; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Obesity; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Management of rosiglitazone-induced edema: two case reports and a review of the literature.
Topics: Body Weight; Clinical Trials as Topic; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diuresis; Edema; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Obesity; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
Rosiglitazone: potential beneficial impact on cardiovascular disease.
Topics: Albuminuria; Arteriosclerosis; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperglycemia; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Obesity; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Male; Metformin; Middle Aged; Obesity; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hemodynamics; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Obesity; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones | 2003 |
[Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Carbamates; Contraindications; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Fasting; Follow-Up Studies; Germany; Glucosamine; Glyburide; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Imino Pyranoses; Insulin; Metformin; Middle Aged; Nateglinide; Obesity; Patient Compliance; Phenylalanine; Pioglitazone; Piperidines; Practice Guidelines as Topic; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors | 2003 |
[Alcoholic and non-alcoholic steatohepatitis].
Topics: Alcoholism; Biopsy; Cholagogues and Choleretics; Diagnosis, Differential; Fatty Liver; Fatty Liver, Alcoholic; Gemfibrozil; Hepatitis; Hepatitis, Alcoholic; Humans; Hypolipidemic Agents; Insulin Resistance; Liver; Liver Transplantation; Middle Aged; Obesity; Pilot Projects; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Ultrasonography; Ursodeoxycholic Acid; Weight Loss | 2004 |
[Inflammation and diabetes].
Topics: Adiponectin; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Blood Glucose; Body Weight; C-Reactive Protein; Chronic Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Exercise; Humans; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Inflammation; Inflammation Mediators; Insulin; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Metabolic Syndrome; Obesity; Research; Risk Factors; Rosiglitazone; Thiazolidinediones | 2004 |
[Glucose-independent impact of the glitazones on the cardiovascular outcome].
Topics: Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Resistance; Longitudinal Studies; Middle Aged; Obesity; Pioglitazone; Primary Prevention; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones | 2005 |
The Clinical Significance of PPAR Gamma Agonism.
Topics: Animals; Blood Glucose; Blood Pressure; Cardiovascular System; Coagulants; Cytokines; Diabetes Mellitus, Type 2; Female; Humans; Inflammation; Insulin Resistance; Islets of Langerhans; Male; Models, Biological; Models, Chemical; Obesity; Phenotype; Pioglitazone; PPAR gamma; Prognosis; Risk Factors; Rosiglitazone; Thiazolidinediones; Time Factors; Triglycerides | 2005 |
[Medical management of primary nonalcoholic fatty liver disease].
Topics: Anti-Obesity Agents; Anticholesteremic Agents; Atorvastatin; Chromans; Diabetes Mellitus, Type 2; Fatty Liver; Heptanoic Acids; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Metabolic Syndrome; Metformin; Obesity; Orlistat; Prevalence; Pyrroles; Rosiglitazone; Thiazolidinediones; Troglitazone | 2005 |
[Regulation of energy metabolism by AMPK: a novel therapeutic approach for the treatment of metabolic and cardiovascular diseases].
Topics: Adenosine Monophosphate; Adenosine Triphosphate; Adipogenesis; Allosteric Regulation; AMP-Activated Protein Kinases; Animals; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Drug Design; Energy Intake; Energy Metabolism; Enzyme Activation; Fatty Acids; Glucose; Homeostasis; Humans; Hypothalamus; Lipogenesis; Mammals; Metformin; Models, Biological; Multienzyme Complexes; Myocardium; Obesity; Phosphorylation; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Subunits; Rosiglitazone; Thiazolidinediones | 2006 |
Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK.
Topics: Combined Modality Therapy; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Economics, Pharmaceutical; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Models, Economic; Obesity; Quality-Adjusted Life Years; Rosiglitazone; Thiazolidinediones; United Kingdom | 2006 |
Cost-effectiveness of rosiglitazone oral combination for the treatment of type 2 diabetes in Germany.
Topics: Administration, Oral; Adult; Aged; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Economics, Pharmaceutical; Female; Germany; Glycated Hemoglobin; Hospitalization; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Models, Economic; Obesity; Quality-Adjusted Life Years; Rosiglitazone; Thiazolidinediones | 2006 |
Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.
Topics: Adult; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Economics, Pharmaceutical; Female; Hospitalization; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Obesity; Quality-Adjusted Life Years; Rosiglitazone; Spain; Thiazolidinediones | 2006 |
[The importance of syndrome X in daily practice].
Topics: Anthropometry; Cardiovascular Diseases; Diet, Reducing; Exercise; Humans; Hyperinsulinism; Hypertension; Hypertriglyceridemia; Hypoglycemic Agents; Insulin Resistance; Lipoproteins, HDL; Lipoproteins, LDL; Obesity; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
33 trial(s) available for rosiglitazone and Obesity
Article | Year |
---|---|
Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome: a randomized controlled trial.
Topics: Adult; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity; Polycystic Ovary Syndrome; Prospective Studies; Rosiglitazone; Treatment Outcome; Waist Circumference; Young Adult | 2020 |
Youth-onset type 2 diabetes mellitus: lessons learned from the TODAY study.
Topics: Adolescent; Blood Glucose; Child; Combined Modality Therapy; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Obesity; Risk Reduction Behavior; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2014 |
Impact of rosiglitazone on body composition, hepatic fat, fatty acids, adipokines and glucose in persons with impaired fasting glucose or impaired glucose tolerance: a sub-study of the DREAM trial.
Topics: Absorptiometry, Photon; Adipokines; Adult; Blood Glucose; Body Composition; Diabetes Mellitus, Type 2; Fatty Acids; Fatty Acids, Nonesterified; Female; Glucose; Humans; Intra-Abdominal Fat; Liver; Male; Obesity; Rosiglitazone; Thiazolidinediones; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Tissue factor expression in obese type 2 diabetic subjects and its regulation by antidiabetic agents.
Topics: Adult; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Gene Expression Regulation; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Obesity; Rosiglitazone; Thiazolidinediones; Thromboplastin | 2015 |
Effect of Recombinant Human Growth Hormone and Rosiglitazone for HIV-Associated Abdominal Fat Accumulation on Adiponectin and other Markers of Inflammation.
Topics: Abdominal Fat; Adiponectin; Adult; Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Drug Therapy, Combination; Female; HIV Infections; Human Growth Hormone; Humans; Hypoglycemic Agents; Interleukin-6; Male; Middle Aged; Obesity; Rosiglitazone; Thiazolidinediones; Young Adult | 2016 |
[Effects of rosiglitazone on inflammatory reaction and insulin resistance in obese patients with newly diagnosed type 2 diabetes].
Topics: Adult; Aged; Aged, 80 and over; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Interleukin-1beta; Interleukin-6; Male; Middle Aged; Obesity; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2008 |
Rosiglitazone improves glucose metabolism in obese adolescents with impaired glucose tolerance: a pilot study.
Topics: Adolescent; Body Composition; Body Weight; Double-Blind Method; Female; Glucose; Glucose Intolerance; Humans; Hypoglycemic Agents; Male; Obesity; Patient Compliance; Pilot Projects; Placebos; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2011 |
Effects of metformin and rosiglitazone on peripheral insulin resistance and β-cell function in obesity: a double-blind, randomized, controlled study.
Topics: Administration, Oral; Adult; Anthropometry; Asian People; Body Composition; China; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Metformin; Middle Aged; Obesity; Rosiglitazone; Thiazolidinediones; Young Adult | 2011 |
A randomized controlled trial of the effect of rosiglitazone and clomiphene citrate versus clomiphene citrate alone in overweight/obese women with polycystic ovary syndrome.
Topics: Adult; Blood Glucose; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; Hypoglycemic Agents; Infertility, Female; Insulin; Insulin Resistance; Obesity; Ovulation Induction; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Rate; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Young Adult | 2012 |
[Investigation of amylin level changes among obese patients at different glucose metabolic states and effects of rosiglitazone intervention].
Topics: Adult; Diabetes Mellitus, Type 2; Female; Glucose; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Islet Amyloid Polypeptide; Islets of Langerhans; Male; Middle Aged; Obesity; Rosiglitazone; Thiazolidinediones | 2011 |
Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer.
Topics: Administration, Oral; Aged; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Metformin; Middle Aged; Obesity; Overweight; Postmenopause; Rosiglitazone; Thiazolidinediones; Time Factors | 2013 |
The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients.
Topics: Aged; Blood Glucose; Blood Pressure; C-Peptide; Circadian Rhythm; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucose Clamp Technique; Glycated Hemoglobin; Glycolysis; Humans; Hypoglycemic Agents; Insulin; Insulin Aspart; Male; Metformin; Middle Aged; Obesity; Rosiglitazone; Thiazolidinediones | 2003 |
Evidence for a potent antiinflammatory effect of rosiglitazone.
Topics: Adult; Aged; Anti-Inflammatory Agents; Blood Glucose; C-Reactive Protein; Chemokine CCL2; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; I-kappa B Proteins; Insulin; Insulin Resistance; Intercellular Adhesion Molecule-1; Leukocytes, Mononuclear; Male; Middle Aged; NF-kappa B; Obesity; Rosiglitazone; Solubility; Thiazolidinediones; Transcription Factor RelA; Tumor Necrosis Factor-alpha | 2004 |
Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens.
Topics: Biopsy; Blood Glucose; Fatty Liver; Female; Fibrosis; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Liver Function Tests; Male; Middle Aged; Obesity; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Tomography, X-Ray Computed; Transcription Factors | 2004 |
[Anti-hypertensive effect of rosiglitazone in non-diabetic essential hypertension].
Topics: Adult; Antihypertensive Agents; Blood Glucose; Blood Pressure; Female; Humans; Hypertension; Insulin Resistance; Male; Middle Aged; Obesity; Rosiglitazone; Thiazolidinediones | 2004 |
The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin-resistant subjects.
Topics: Adult; Apolipoproteins B; Biomarkers; Blood Glucose; Fatty Acids, Nonesterified; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Lipids; Male; Metformin; Middle Aged; Obesity; Postprandial Period; Rosiglitazone; Thiazolidinediones; Triglycerides | 2005 |
The effect of rosiglitazone on overweight subjects with type 1 diabetes.
Topics: Adult; Blood Glucose; Body Mass Index; Body Size; C-Peptide; Diabetes Mellitus, Type 1; Double-Blind Method; Ethnicity; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Obesity; Placebos; Rosiglitazone; Thiazolidinediones; Weight Gain | 2005 |
Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome.
Topics: Adult; Biomarkers; Body Weight; C-Reactive Protein; Endothelium, Vascular; Female; Hormones; Humans; Hypoglycemic Agents; Insulin Resistance; Muscle, Smooth, Vascular; Obesity; Polycystic Ovary Syndrome; Rosiglitazone; Thiazolidinediones; Vasculitis | 2005 |
Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Cholesterol, HDL; Cyproterone Acetate; Drug Therapy, Combination; Ethinyl Estradiol; Female; Hirsutism; Humans; Insulin; Insulin Resistance; Middle Aged; Obesity; Polycystic Ovary Syndrome; Rosiglitazone; Thiazolidinediones | 2006 |
Discrepancies in the regulation of plasma adiponectin and TNF-alpha levels and adipose tissue gene expression in obese African Americans with glucose intolerance: a pilot study using rosiglitazone.
Topics: Adiponectin; Adipose Tissue; Adult; Black or African American; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Gene Expression; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Longitudinal Studies; Male; Middle Aged; Obesity; Pilot Projects; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2005 |
Fluid retention and vascular effects of rosiglitazone in obese, insulin-resistant, nondiabetic subjects.
Topics: Adult; Blood Pressure; Capillary Permeability; Edema; Female; Forearm; Humans; Insulin; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Obesity; omega-N-Methylarginine; Plasma Volume; Regional Blood Flow; Rosiglitazone; Thiazolidinediones; Vasodilation | 2006 |
Comparison of metformin versus rosiglitazone in patients with Acanthosis nigricans: a pilot study.
Topics: Acanthosis Nigricans; Administration, Oral; Adult; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Obesity; Pilot Projects; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2006 |
Rosiglitazone treatment alleviates inflammation and improves liver function in overweight women with polycystic ovary syndrome: a randomized placebo-controlled study.
Topics: Adolescent; Adult; Female; Humans; Hypoglycemic Agents; Inflammation; Liver Diseases; Obesity; Polycystic Ovary Syndrome; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2007 |
Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 alpha and PPAR beta/delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus.
Topics: Biopsy; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Gene Expression Regulation; Heat-Shock Proteins; Humans; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Male; Middle Aged; Mitochondria, Muscle; Mitochondrial Proteins; Muscle, Skeletal; Obesity; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; PPAR-beta; Rosiglitazone; Thiazolidinediones; Transcription Factors | 2007 |
Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonists on 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adult; Aged; Cortisone; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; Fenofibrate; Gas Chromatography-Mass Spectrometry; Hormone Antagonists; Humans; Hydrocortisone; Hypolipidemic Agents; Insulin Resistance; Kinetics; Liver; Male; Metyrapone; Microdialysis; Middle Aged; Mifepristone; Obesity; PPAR alpha; PPAR gamma; Rosiglitazone; Subcutaneous Fat; Thiazolidinediones | 2007 |
Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non-diabetic patients.
Topics: Adipose Tissue; Adolescent; Adult; Aged; B-Lymphocytes; Blood Glucose; Body Composition; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Male; Metformin; Middle Aged; Obesity; Obesity, Morbid; Rosiglitazone; Thiazolidinediones; Weight Loss | 2008 |
Beneficial effects of combined treatment with rosiglitazone and exercise on cardiovascular risk factors in patients with type 2 diabetes.
Topics: Aged; Cardiovascular Diseases; Combined Modality Therapy; Diabetes Mellitus, Type 2; Exercise Therapy; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Obesity; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
[The effect of rosiglitazone on plasma adiponectin and resistin levels in obese PCO woman--preliminary report].
Topics: Adiponectin; Adolescent; Adult; Body Mass Index; Case-Control Studies; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Middle Aged; Obesity; Polycystic Ovary Syndrome; Resistin; Rosiglitazone; Thiazolidinediones; Triglycerides | 2007 |
Adiponectin mediates the suppressive effect of rosiglitazone on plasminogen activator inhibitor-1 production.
Topics: 3T3-L1 Cells; Adenoviridae; Adipocytes; Adiponectin; Adipose Tissue; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Fats; Disease Models, Animal; Fibrinolytic Agents; Genetic Vectors; Humans; Hypoglycemic Agents; Mice; Mice, Inbred C57BL; Mice, Knockout; Obesity; Plasminogen Activator Inhibitor 1; PPAR gamma; Recombinant Proteins; RNA, Messenger; Rosiglitazone; Serpin E2; Serpins; Sulfonylurea Compounds; Thiazolidinediones; Transduction, Genetic; Treatment Outcome | 2007 |
Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone.
Topics: Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Lipids; Male; Metformin; Obesity; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2008 |
Reduction of proteinuria by rosiglitazone in non-diabetic renal disease.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Body Mass Index; Cross-Over Studies; Diabetes Mellitus; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Obesity; PPAR gamma; Proteinuria; Retrospective Studies; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2008 |
Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin.
Topics: Adiponectin; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Italy; Leptin; Male; Metformin; Middle Aged; Obesity; Overweight; Resistin; Rosiglitazone; Single-Blind Method; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2008 |
Rosiglitazone amplifies the benefits of lifestyle intervention measures in long-standing type 2 diabetes mellitus.
Topics: Biomarkers; Blood Pressure; Body Constitution; Body Mass Index; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Life Style; Obesity; Placebos; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides; Weight Loss | 2002 |
234 other study(ies) available for rosiglitazone and Obesity
Article | Year |
---|---|
Discovery of novel dual functional agent as PPARgamma agonist and 11beta-HSD1 inhibitor for the treatment of diabetes.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Body Weight; Diabetes Mellitus, Experimental; Fats; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Mice; Models, Molecular; Obesity; Phenylpropionates; PPAR gamma; Rats; Rats, Wistar | 2009 |
Identification of diaryl ether-based ligands for estrogen-related receptor α as potential antidiabetic agents.
Topics: Administration, Oral; Animals; Binding, Competitive; Biological Availability; Crystallography, X-Ray; Diabetes Mellitus; Dogs; ERRalpha Estrogen-Related Receptor; Ethers; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Ligands; Macaca fascicularis; Male; Mice; Mice, Knockout; Models, Molecular; Molecular Structure; Obesity; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Structure-Activity Relationship; Thiazolidinediones; Triglycerides | 2011 |
Synthesis and biological evaluation of 5-benzylidenepyrimidine-2,4,6(1H,3H,5H)-trione derivatives for the treatment of obesity-related nonalcoholic fatty liver disease.
Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Alanine Transaminase; Animals; Barbiturates; Body Weight; Cholesterol; Diet, High-Fat; Disease Models, Animal; Fatty Liver; Female; Glucose; Glucose Tolerance Test; Hep G2 Cells; Humans; Insulin; Insulin Resistance; Leptin; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Obesity; Piperidines; Pyrimidines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Tissue Distribution; Triglycerides | 2012 |
Macrophage membrane-camouflaged lipoprotein nanoparticles for effective obesity treatment based on a sustainable self-reinforcement strategy.
Topics: Animals; Cyclic Nucleotide Phosphodiesterases, Type 5; Hypoglycemic Agents; Lipoproteins; Lipoproteins, HDL; Macrophages; Mice; Mice, Inbred C57BL; Mice, Obese; Nanoparticles; Obesity; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Sildenafil Citrate; Treatment Outcome | 2022 |
Chronic cAMP activation induces adipocyte browning through discordant biphasic remodeling of transcriptome and chromatin accessibility.
Topics: Adipocytes, Beige; Chromatin; Cyclic AMP; Humans; Obesity; PPAR gamma; Rosiglitazone; Thermogenesis; Transcriptome | 2022 |
miR-223 Plays a Key Role in Obesogen-Enhanced Adipogenesis in Mesenchymal Stem Cells and in Transgenerational Obesity.
Topics: Adipogenesis; Animals; Cell Differentiation; Female; Male; Mesenchymal Stem Cells; Mice; MicroRNAs; Obesity; PPAR gamma; Pregnancy; Rosiglitazone | 2023 |
Effects of Fatty Acid Metabolites on Adipocytes Britening: Role of Thromboxane A2.
Topics: Adipocytes, Brown; Fatty Acids; Humans; Obesity; Prostaglandins I; Rosiglitazone; Thromboxane A2 | 2023 |
Head-to-head comparison of BAM15, semaglutide, rosiglitazone, NEN, and calorie restriction on metabolic physiology in female db/db mice.
Topics: Animals; Caloric Restriction; Diabetes Mellitus, Type 2; Ethanolamine; Ethanolamines; Female; Mice; Niclosamide; Non-alcoholic Fatty Liver Disease; Obesity; Rosiglitazone | 2024 |
Tetrahydrocannabinolic acid A (THCA-A) reduces adiposity and prevents metabolic disease caused by diet-induced obesity.
Topics: 3T3-L1 Cells; Adipogenesis; Adiposity; Animals; Anti-Inflammatory Agents; Cells, Cultured; Diet, High-Fat; Dronabinol; Fatty Liver; HEK293 Cells; Humans; Male; Metabolic Diseases; Mice; Mice, Inbred C57BL; Obesity; PPAR gamma; Rosiglitazone | 2020 |
Metformin, rosiglitazone, or both for obese women with polycystic ovary syndrome?
Topics: Female; Humans; Hypoglycemic Agents; Metformin; Obesity; Polycystic Ovary Syndrome; Rosiglitazone | 2020 |
Adipocytes fail to maintain cellular identity during obesity due to reduced PPARγ activity and elevated TGFβ-SMAD signaling.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Adipose Tissue; Animals; Cell Differentiation; Diet, High-Fat; Humans; Insulin; Insulin Resistance; Mice; Mice, Inbred C57BL; Mice, Transgenic; Obesity; PPAR gamma; Rosiglitazone; Signal Transduction; Smad Proteins; Transforming Growth Factor beta | 2020 |
A novel dual-targeted rosiglitazone-loaded nanoparticle for the prevention of diet-induced obesity via the browning of white adipose tissue.
Topics: Adipose Tissue, White; Animals; Diet; Diet, High-Fat; Energy Metabolism; Mice; Mice, Inbred C57BL; Nanoparticles; Obesity; Rosiglitazone | 2021 |
Photoacoustic molecular imaging-escorted adipose photodynamic-browning synergy for fighting obesity with virus-like complexes.
Topics: Adipose Tissue, White; Animals; Hepatitis B; Humans; Indoles; Mice; Molecular Imaging; Obesity; Organometallic Compounds; Photoacoustic Techniques; Rosiglitazone; Viral Core Proteins | 2021 |
Combined treatment with FABP4 inhibitor ameliorates rosiglitazone-induced liver steatosis in obese diabetic db/db mice.
Topics: Animals; Diabetes Mellitus, Type 2; Drug Combinations; Fatty Acid-Binding Proteins; Fatty Liver; Hepatocytes; Lipid Metabolism; Liver; Male; Mice; Mice, Inbred C57BL; Models, Animal; Obesity; Primary Cell Culture; Rosiglitazone; Triglycerides | 2021 |
Rosiglitazone Requires Hepatocyte PPARγ Expression to Promote Steatosis in Male Mice With Diet-Induced Obesity.
Topics: Animals; Diet, High-Fat; Hepatocytes; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Obesity; PPAR gamma; Rosiglitazone | 2021 |
Caffeic acid and hydroxytyrosol have anti-obesogenic properties in zebrafish and rainbow trout models.
Topics: Animals; Anti-Obesity Agents; Caffeic Acids; Models, Biological; Obesity; Oncorhynchus mykiss; Phenylethyl Alcohol; PPAR gamma; Rosiglitazone; Signal Transduction; Thiazolidinediones; Zebrafish | 2017 |
Rosiglitazone Improves Insulin Resistance Mediated by 10,12 Conjugated Linoleic Acid in a Male Mouse Model of Metabolic Syndrome.
Topics: 3T3-L1 Cells; Adipose Tissue; Animals; Body Weight; Disease Models, Animal; Glucose; Insulin Resistance; Linoleic Acids, Conjugated; Liver; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mice, Knockout; Obesity; Receptors, LDL; Rosiglitazone; Thiazolidinediones | 2017 |
Locally Induced Adipose Tissue Browning by Microneedle Patch for Obesity Treatment.
Topics: Adipocytes, White; Adipose Tissue, White; Animals; Anti-Obesity Agents; Drug Delivery Systems; Hypoglycemic Agents; Male; Mice, Inbred C57BL; Obesity; Rosiglitazone; Transdermal Patch | 2017 |
Rosiglitazone is superior to resveratrol in inducing the expression of glyceroneogenic genes in adipose tissue from obese participants.
Topics: Adipose Tissue; Adult; Female; Gene Expression Regulation; Humans; Male; Middle Aged; Obesity; Pregnancy; Resveratrol; Rosiglitazone; Stilbenes; Thiazolidinediones; Tissue Culture Techniques | 2018 |
Identification and expression patterns of adipokine genes during adipocyte differentiation in the Tibetan goat (Capra hircus).
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Adipokines; Adipose Tissue; Animals; Apelin; Cell Differentiation; Female; Fibroblast Growth Factors; Goats; Lipid Metabolism; Mice; Nicotinamide Phosphoribosyltransferase; Obesity; Resistin; Rosiglitazone; Subcutaneous Fat; Thiazolidinediones | 2018 |
Role of peroxisome proliferator-activated receptor-gamma activation on visfatin, advanced glycation end products, and renal oxidative stress in obesity-induced type 2 diabetes mellitus.
Topics: Animals; Antioxidants; Blood Glucose; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glycation End Products, Advanced; Hypoglycemic Agents; Insulin; Kidney; Lipid Peroxidation; Nicotinamide Phosphoribosyltransferase; Obesity; Oxidative Stress; PPAR gamma; Rats, Wistar; Rosiglitazone; Signal Transduction; Streptozocin | 2018 |
PPARγ deacetylation dissociates thiazolidinedione's metabolic benefits from its adverse effects.
Topics: Acetylation; Adipose Tissue, White; Animals; Body Weight; Energy Metabolism; Female; Hypoglycemic Agents; Insulin; Male; Mice; Mice, Transgenic; Obesity; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2018 |
Palmitoyl lactic acid induces adipogenesis and a brown fat-like phenotype in 3T3-L1 preadipocytes.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Adipose Tissue, Brown; Animals; Cell Differentiation; Lactic Acid; Lipid Droplets; Mice; Obesity; Palmitates; Phenotype; Pioglitazone; PPAR gamma; Rosiglitazone | 2018 |
An Hsp20-FBXO4 Axis Regulates Adipocyte Function through Modulating PPARγ Ubiquitination.
Topics: Adipocytes; Adipose Tissue, White; Adiposity; Animals; Cold Temperature; Energy Metabolism; F-Box Proteins; Glucose; HSP20 Heat-Shock Proteins; Inflammation; Insulin Resistance; Lipid Metabolism; Mice, Inbred C57BL; Mice, Knockout; Obesity; PPAR gamma; Protein Stability; RNA, Messenger; Rosiglitazone; Ubiquitination | 2018 |
PPARγ Deficiency Suppresses the Release of IL-1β and IL-1α in Macrophages via a Type 1 IFN-Dependent Mechanism.
Topics: Animals; Cells, Cultured; Inflammasomes; Inflammation; Interferon Type I; Interleukin-1alpha; Interleukin-1beta; Macrophage Activation; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; NLR Family, Pyrin Domain-Containing 3 Protein; Obesity; PPAR gamma; Rosiglitazone; Sequence Analysis, RNA | 2018 |
Electrophilic nitro-oleic acid reverses obesity-induced hepatic steatosis.
Topics: Adipose Tissue; Animals; Biomarkers; Blood Glucose; Body Weight; Diet, High-Fat; Disease Models, Animal; Glucose Intolerance; Hepatocytes; Lipid Metabolism; Male; Mice; Mitochondria, Liver; Non-alcoholic Fatty Liver Disease; Obesity; Oleic Acids; Protective Agents; Rosiglitazone; Triglycerides | 2019 |
In vivo multi-tissue efficacy of peroxisome proliferator-activated receptor-γ therapy on glucose and fatty acid metabolism in obese type 2 diabetic rats.
Topics: Adipose Tissue, Brown; Animals; Diabetes Mellitus, Type 2; Glucose; Hypoglycemic Agents; Insulin; Lipid Metabolism; Liver; Muscle, Skeletal; Obesity; PPAR gamma; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones | 2013 |
Oral green tea catechins transiently lower plasma glucose concentrations in female db/db mice.
Topics: Adiponectin; Adipose Tissue; Animals; Anti-Inflammatory Agents; Blood Glucose; Camellia sinensis; Catechin; Diabetes Mellitus, Type 2; Dietary Supplements; Female; Flavonoids; Hyperglycemia; Hypoglycemic Agents; Inflammation; Intercellular Adhesion Molecule-1; Mice; Mice, Knockout; Mice, Obese; Obesity; Phytotherapy; Plant Extracts; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha; Weight Gain | 2013 |
6-gingerol inhibits rosiglitazone-induced adipogenesis in 3T3-L1 adipocytes.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Animals; Catechols; CCAAT-Enhancer-Binding Protein-alpha; Cell Differentiation; Down-Regulation; Fatty Acid Synthases; Fatty Acid-Binding Proteins; Fatty Alcohols; Mice; Obesity; PPAR gamma; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Triglycerides | 2014 |
Protein sets define disease states and predict in vivo effects of drug treatment.
Topics: Adipose Tissue, White; Animals; Diet, High-Fat; Hypoglycemic Agents; Liver; Male; Mice; Mice, Inbred C57BL; Myocardium; Obesity; PPAR gamma; Protein Processing, Post-Translational; Proteomics; Rosiglitazone; Salicylates; Thiazolidinediones | 2013 |
PPAR agonist-induced reduction of Mcp1 in atherosclerotic plaques of obese, insulin-resistant mice depends on adiponectin-induced Irak3 expression.
Topics: Adipocytes; Adiponectin; Animals; Chemokine CCL2; Diet, High-Fat; Fenofibrate; Inflammation; Insulin; Insulin Resistance; Interleukin-1 Receptor-Associated Kinases; Leptin; Macrophages; Mice; Mice, Inbred C57BL; Obesity; Peroxisome Proliferator-Activated Receptors; Plaque, Atherosclerotic; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2013 |
Adipose tissue-related proteins locally associated with resolution of inflammation in obese mice.
Topics: Adipocytes; Adipokines; Adipose Tissue, White; Animals; Diet, High-Fat; Dietary Fats; Docosahexaenoic Acids; Energy Metabolism; Enzyme-Linked Immunosorbent Assay; Fatty Acids, Omega-3; Immunohistochemistry; Inflammation; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Real-Time Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones | 2014 |
Rosiglitazone-loaded nanospheres for modulating macrophage-specific inflammation in obesity.
Topics: Adipose Tissue, White; Animals; Anti-Inflammatory Agents; Bone Marrow Cells; Cell Line; Cells, Cultured; Gene Expression Regulation; Hepatitis; Hypoglycemic Agents; Inflammation; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardium; Nanospheres; Obesity; Polyvinyl Alcohol; Receptors, LDL; Rosiglitazone; Thiazolidinediones | 2013 |
The expression of FTO in human adipose tissue is influenced by fat depot, adiposity, and insulin sensitivity.
Topics: 3T3-L1 Cells; Adipogenesis; Adipose Tissue; Adiposity; Adult; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Animals; Body Mass Index; Cell Differentiation; Diabetes Mellitus, Type 2; Female; Gene Expression; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Mice; Middle Aged; Obesity; Omentum; PPAR gamma; Proteins; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2013 |
A role for adipocyte-derived lipopolysaccharide-binding protein in inflammation- and obesity-associated adipose tissue dysfunction.
Topics: Acute-Phase Proteins; Adipocytes; Adipose Tissue; Adult; Animals; Carrier Proteins; Humans; In Vitro Techniques; Inflammation; Insulin Resistance; Lipopolysaccharides; Male; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Middle Aged; Obesity; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2013 |
Inflammation and insulin resistance exert dual effects on adipose tissue tumor protein 53 expression.
Topics: Adipocytes; Adipogenesis; Adipose Tissue; Analysis of Variance; Animals; Bariatric Surgery; Diet, High-Fat; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression; Genes, p53; Humans; Inflammation; Insulin Resistance; Male; Metformin; Mice; Mice, Knockout; Obesity; Omentum; Rosiglitazone; Thiazolidinediones | 2014 |
APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Apolipoprotein E3; Atorvastatin; Cholesterol Ester Transfer Proteins; Disease Models, Animal; Fenofibrate; Glucagon-Like Peptide 1; Heptanoic Acids; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Liraglutide; Male; Metabolic Syndrome; Mice, Transgenic; Niacin; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Rosiglitazone; Thiazolidinediones | 2014 |
Rosiglitazone and fenofibrate exacerbate liver steatosis in a mouse model of obesity and hyperlipidemia. A transcriptomic and metabolomic study.
Topics: Animals; Disease Models, Animal; Fatty Liver; Fenofibrate; Gene Expression Profiling; Gene Expression Regulation; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Liver; Male; Metabolome; Mice; Mice, Transgenic; Obesity; Peroxisome Proliferator-Activated Receptors; Protein Interaction Mapping; Rosiglitazone; Signal Transduction; Thiazolidinediones; Transcriptome | 2014 |
Midkine, a potential link between obesity and insulin resistance.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Cell Differentiation; Cytokines; Female; Glucose Transporter Type 4; Humans; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; Mice; Middle Aged; Midkine; Obesity; Phosphorylation; Rosiglitazone; Signal Transduction; Suppressor of Cytokine Signaling Proteins; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2014 |
[The protective effects of rosiglitazone on kidney in diet-induced obese rats].
Topics: Animals; Body Weight; Diet, High-Fat; Fatty Acids, Nonesterified; Intra-Abdominal Fat; Kidney Glomerulus; Nitric Oxide; Obesity; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Triglycerides; Vascular Endothelial Growth Factor A; Vasodilation | 2014 |
Therapeutic administration of orlistat, rosiglitazone, or the chemokine receptor antagonist RS102895 fails to improve the severity of acute pancreatitis in obese mice.
Topics: Acute Disease; Animals; Anti-Obesity Agents; Benzoxazines; Interleukin-12; Interleukin-18; Lactones; Male; Mice, Inbred C57BL; Obesity; Orlistat; Pancreatitis; Piperidines; Receptors, CCR2; Rosiglitazone; Severity of Illness Index; Thiazolidinediones; Treatment Failure; Vasodilator Agents | 2014 |
Altered expression profile of renal α(1D)-adrenergic receptor in diabetes and its modulation by PPAR agonists.
Topics: Animals; Cell Dedifferentiation; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fenofibrate; Gene Expression Profiling; Hypoglycemic Agents; Kidney; Kidney Glomerulus; Kidney Tubules; Male; Obesity; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; Rats; Rats, Zucker; Receptors, Adrenergic, alpha-1; Rosiglitazone; Thiazolidinediones; Up-Regulation | 2014 |
Integrative analysis of transcriptomics, proteomics, and metabolomics data of white adipose and liver tissue of high-fat diet and rosiglitazone-treated insulin-resistant mice identified pathway alterations and molecular hubs.
Topics: Adipose Tissue, White; Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Gene Expression Profiling; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Metabolic Networks and Pathways; Metabolomics; Mice, Inbred C57BL; Obesity; Proteomics; Rosiglitazone; Tandem Mass Spectrometry; Thiazolidinediones; Transcriptome | 2014 |
The Demethylase Activity of FTO (Fat Mass and Obesity Associated Protein) Is Required for Preadipocyte Differentiation.
Topics: 3T3-L1 Cells; Adenosine; Adipocytes; Adipogenesis; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Animals; Biomarkers; Cell Differentiation; DNA Methylation; DNA Modification Methylases; Gene Expression Profiling; Hypoglycemic Agents; Mice; Obesity; PPAR gamma; Proteins; RNA, Small Interfering; Rosiglitazone; Thiazolidinediones | 2015 |
Effects of PPARγ agonist on heart rate variability and cardiac mitochondrial function in obese-insulin resistant rats.
Topics: Animals; Heart Rate; Insulin Resistance; Male; Mitochondria, Heart; Obesity; PPAR gamma; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2015 |
Hybrid nanoparticles improve targeting to inflammatory macrophages through phagocytic signals.
Topics: Animals; Anti-Inflammatory Agents; Apolipoproteins E; Atherosclerosis; Cell Line; Cholesterol; Cytokines; Fluorescein-5-isothiocyanate; Gadolinium; Macrophages; Mice, Inbred C57BL; Mice, Knockout; Nanoparticles; Obesity; Paclitaxel; Phagocytosis; Phosphatidylethanolamines; Phosphatidylserines; Phospholipases A2; Polyethylene Glycols; Polystyrenes; Rosiglitazone; Tamoxifen; Thiazolidinediones | 2015 |
Developmental Programming: Impact of Gestational Steroid and Metabolic Milieus on Adiposity and Insulin Sensitivity in Prenatal Testosterone-Treated Female Sheep.
Topics: Adiposity; Animals; Disease Models, Animal; Embryonic Development; Female; Flutamide; Insulin Resistance; Obesity; Polycystic Ovary Syndrome; Pregnancy; Prenatal Exposure Delayed Effects; Rosiglitazone; Sheep; Testosterone; Thiazolidinediones | 2016 |
Ursolic acid and rosiglitazone combination improves insulin sensitivity by increasing the skeletal muscle insulin-stimulated IRS-1 tyrosine phosphorylation in high-fat diet-fed C57BL/6J mice.
Topics: Animals; Anti-Obesity Agents; Antioxidants; Diabetes Mellitus, Type 2; Diet, High-Fat; Drug Therapy, Combination; Glucose Transporter Type 4; Hypoglycemic Agents; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; Mice, Inbred C57BL; Muscle, Skeletal; Obesity; Phosphatidylinositol 3-Kinase; Phosphorylation; Protein Processing, Post-Translational; Protein Transport; Rosiglitazone; Second Messenger Systems; Thiazolidinediones; Triterpenes; Ursolic Acid; Weight Gain | 2016 |
Preventing diet-induced obesity in mice by adipose tissue transformation and angiogenesis using targeted nanoparticles.
Topics: 16,16-Dimethylprostaglandin E2; Adipose Tissue, Brown; Adipose Tissue, White; Animals; Carbohydrate Metabolism; Diet; Drug Delivery Systems; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Nanomedicine; Nanoparticles; Neovascularization, Physiologic; Obesity; Rosiglitazone; Thiazolidinediones | 2016 |
Effect of selective expression of dominant-negative PPARγ in pro-opiomelanocortin neurons on the control of energy balance.
Topics: 3T3 Cells; Adipogenesis; Animals; Body Weight; Brain; Cell Line; Diet, High-Fat; Energy Metabolism; Female; HEK293 Cells; Homeostasis; Humans; Leptin; Male; Mice; Neurons; Obesity; PPAR gamma; Pro-Opiomelanocortin; Rosiglitazone; Thiazolidinediones; Weight Gain | 2016 |
FKBP51 Null Mice Are Resistant to Diet-Induced Obesity and the PPARγ Agonist Rosiglitazone.
Topics: Adiposity; Animals; Energy Metabolism; Fatty Liver; Glucose Intolerance; Intra-Abdominal Fat; Lipid Metabolism; Lipids; Male; Mice, Knockout; Obesity; PPAR gamma; Rosiglitazone; Tacrolimus Binding Proteins; Thiazolidinediones; Weight Gain | 2016 |
NAMPT-Mediated NAD(+) Biosynthesis in Adipocytes Regulates Adipose Tissue Function and Multi-organ Insulin Sensitivity in Mice.
Topics: Adipocytes; Adiponectin; Adipose Tissue; Animals; Cyclin-Dependent Kinase 5; Cytokines; Fatty Acids, Nonesterified; Female; Gene Expression Regulation; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Mice; Mice, Knockout; Muscle, Skeletal; Nicotinamide Mononucleotide; Nicotinamide Phosphoribosyltransferase; Obesity; Phosphorylation; PPAR gamma; Rosiglitazone; Signal Transduction; Thiazolidinediones | 2016 |
FGF21 Is Not a Major Mediator for Bone Homeostasis or Metabolic Actions of PPARα and PPARγ Agonists.
Topics: Animals; Bone Density; Dietary Fats; Fibroblast Growth Factors; Gene Expression Regulation; Glucose; Homeostasis; Humans; Insulin; Male; Mice; Mice, Knockout; Obesity; Osteoprotegerin; PPAR alpha; PPAR gamma; RANK Ligand; Rosiglitazone; Thiazolidinediones | 2017 |
Reduction of obesity-associated white adipose tissue inflammation by rosiglitazone is associated with reduced non-alcoholic fatty liver disease in LDLr-deficient mice.
Topics: Adipose Tissue, White; Animals; Inflammation; Male; Mice; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Obesity; Receptors, LDL; Rosiglitazone; Thiazolidinediones | 2016 |
Characterization of alendronic- and undecylenic acid coated magnetic nanoparticles for the targeted delivery of rosiglitazone to subcutaneous adipose tissue.
Topics: Adipose Tissue; Animals; Hypoglycemic Agents; Magnetite Nanoparticles; Mice; Mice, Inbred C57BL; Obesity; Rosiglitazone; Subcutaneous Fat; Thiazolidinediones; Tissue Distribution; Undecylenic Acids | 2017 |
Maternal Obesity Programs Senescence Signaling and Glucose Metabolism in Osteo-Progenitors From Rat and Human.
Topics: Adipogenesis; Animals; Cell Proliferation; Cells, Cultured; Cellular Senescence; Female; Glucose; Humans; Insulin Resistance; Male; Mesenchymal Stem Cells; Obesity; Osteogenesis; Rats; Rats, Sprague-Dawley; Rosiglitazone; Signal Transduction; Skull; Thiazolidinediones; Thinness | 2016 |
Peptide-based GLP-1/glucagon co-agonists: A double-edged sword to combat diabesity.
Topics: Animals; Clinical Trials as Topic; Diabetes Complications; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide-1 Receptor; Humans; Mice; Mice, Obese; Obesity; Oxyntomodulin; Peptides; Rats; Receptors, Glucagon; Recombinant Proteins; Rosiglitazone; Thiazolidinediones; Transcription, Genetic; Venoms | 2016 |
Role of the adipose PPARγ-adiponectin axis in susceptibility to stress and depression/anxiety-related behaviors.
Topics: Adipocytes; Adiponectin; Adipose Tissue; Adiposity; Animals; Anxiety; Blood-Brain Barrier; Depression; Female; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Obesity; PPAR gamma; RNA, Messenger; Rosiglitazone; Stress, Psychological; Thiazolidinediones | 2017 |
Anti-Inflammatory Effects of Rosiglitazone in Obesity-Impaired Wound Healing Depend on Adipocyte Differentiation.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Anti-Inflammatory Agents; Cell Differentiation; Chemokine CXCL2; Cyclooxygenase 2; Fatty Acid-Binding Proteins; Female; Kruppel-Like Transcription Factors; Mice; Mice, Obese; Obesity; PPAR gamma; Rosiglitazone; Thiazolidinediones; Wound Healing | 2016 |
FAK signalling controls insulin sensitivity through regulation of adipocyte survival.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue; Adiposity; Adult; Animals; Apoptosis; Cell Survival; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Female; Focal Adhesion Kinase 1; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Obese; Middle Aged; Obesity; PPAR gamma; Primary Cell Culture; Rosiglitazone; Signal Transduction; Thiazolidinediones | 2017 |
Targeting PPARγ in the epigenome rescues genetic metabolic defects in mice.
Topics: Animals; Diet, High-Fat; Epigenesis, Genetic; Hypoglycemic Agents; Intra-Abdominal Fat; Male; Mice, 129 Strain; Mice, Inbred C57BL; Obesity; PPAR gamma; Protein Binding; Regulatory Elements, Transcriptional; Rosiglitazone; Subcutaneous Fat, Abdominal; Thiazolidinediones; Transcriptional Activation; Transcriptome; Uncoupling Protein 1 | 2017 |
Parkin-mediated mitophagy is downregulated in browning of white adipose tissue.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue, Brown; Adipose Tissue, White; Animals; Dioxoles; Down-Regulation; Energy Metabolism; Hypoglycemic Agents; Ion Channels; Male; Mice; Mice, Inbred C57BL; Mitochondria; Mitophagy; Obesity; Rosiglitazone; Thiazolidinediones; Ubiquitin-Protein Ligases; Uncoupling Protein 1 | 2017 |
Cidea is associated with lipid droplets and insulin sensitivity in humans.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue, White; Amino Acid Sequence; Animals; Apoptosis Regulatory Proteins; Body Mass Index; Carrier Proteins; Humans; Insulin Resistance; Lipolysis; Male; Mice; Mice, Inbred C57BL; Molecular Sequence Data; Obesity; Perilipin-1; Phosphoproteins; PPAR gamma; Proteins; RNA Interference; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Triglycerides | 2008 |
Peroxisome proliferator-activated receptor gamma activation promotes infiltration of alternatively activated macrophages into adipose tissue.
Topics: 3T3 Cells; Adipose Tissue; Animals; Cell Line; Diet, Fat-Restricted; Dietary Fats; Inflammation; Liver; Macrophage Activation; Macrophages; Male; Mice; Mice, Inbred Strains; Obesity; PPAR gamma; RNA; Rosiglitazone; Thiazolidinediones; Triglycerides | 2008 |
Dysregulation of adipose glutathione peroxidase 3 in obesity contributes to local and systemic oxidative stress.
Topics: 3T3-L1 Cells; Acetylcysteine; Adipose Tissue; Animals; Antioxidants; Base Sequence; Gene Expression Regulation, Enzymologic; Glutathione Peroxidase; Humans; Hypoxia; Kidney; Lipopolysaccharides; Lung; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Oxidative Stress; PPAR gamma; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2008 |
Chronic rosiglitazone therapy normalizes expression of ACE1, SCD1 and other genes in the kidney of obese Zucker rats as determined by microarray analysis.
Topics: Animals; Chromosome Mapping; Gene Expression Regulation, Enzymologic; Genome; Kidney; Male; Obesity; Oligonucleotide Array Sequence Analysis; Peptidyl-Dipeptidase A; Rats; Rats, Zucker; Rosiglitazone; Stearoyl-CoA Desaturase; Thiazolidinediones | 2008 |
Enhanced angiogenesis in obesity and in response to PPARgamma activators through adipocyte VEGF and ANGPTL4 production.
Topics: Adipocytes, White; Adipose Tissue, White; Angiopoietin-Like Protein 4; Angiopoietins; Animals; Antigens, CD; Cadherins; Capillaries; Cells, Cultured; Culture Media, Conditioned; Epididymis; Gene Expression; Humans; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Neovascularization, Physiologic; Obesity; Pioglitazone; PPAR gamma; RNA, Small Interfering; Rosiglitazone; Thiazolidinediones; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor B | 2008 |
Evaluation of rosiglitazone administration on cardiovascular function in severe obesity.
Topics: Adult; Blood Pressure; Body Weight; Cardiovascular System; Diastole; Echocardiography, Doppler; Female; Humans; Insulin; Insulin Resistance; Male; Obesity; PPAR gamma; Rosiglitazone; Systole; Thiazolidinediones; Ventricular Function, Left | 2008 |
Capillary endothelial but not lymphatic function is restored under rosiglitazone in Zucker diabetic fatty rats.
Topics: Albumins; Animals; Capillaries; Capillary Permeability; Diabetes Mellitus, Type 2; Disease Models, Animal; Endothelium; Lymphatic System; Male; Obesity; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones; Vascular Endothelial Growth Factor A | 2009 |
Rosiglitazone increases testosterone in hypogonadal type 2 diabetic men.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Hypogonadism; Male; Obesity; Rosiglitazone; Testosterone; Thiazolidinediones; Vasodilator Agents | 2009 |
Regulation of angiotensin II type I receptor (AT1R) protein levels in the obese Zucker rat kidney and urine.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphenyl Compounds; Blood Pressure; Disease Models, Animal; Humans; Hypertension; Hypoglycemic Agents; Kidney; Metabolic Syndrome; Obesity; PPAR gamma; Rats; Rats, Zucker; Receptor, Angiotensin, Type 1; Rosiglitazone; Sodium Chloride, Dietary; Tetrazoles; Thiazolidinediones; Thinness | 2009 |
Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins.
Topics: Adiponectin; Adipose Tissue; AMP-Activated Protein Kinases; Animals; Chemokine CCL2; Diet; Dietary Fats; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Fatty Liver; Glucose Transporter Type 4; Hypoglycemic Agents; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; Mice; Mice, Obese; Muscle, Skeletal; Obesity; PPAR gamma; Resistin; Rosiglitazone; Thiazolidinediones | 2009 |
Rosiglitazone aggravates nonalcoholic Fatty pancreatic disease in C57BL/6 mice fed high-fat and high-sucrose diet.
Topics: Adipose Tissue; Animals; Bezafibrate; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Fats; Dietary Sucrose; Energy Metabolism; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Mice; Mice, Inbred C57BL; Obesity; Pancreatic Diseases; PPAR alpha; PPAR-beta; Rosiglitazone; Thiazolidinediones; Weight Gain | 2009 |
Additive action of 11beta-HSD1 inhibition and PPAR-gamma agonism on hepatic steatosis and triglyceridemia in diet-induced obese rats.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adiponectin; Animals; Disease Models, Animal; Fatty Liver; Male; Obesity; PPAR gamma; Rats; Rats, Sprague-Dawley; Receptors, Adiponectin; Rosiglitazone; Thiazolidinediones; Triazoles; Triglycerides | 2009 |
B cell activation factor (BAFF) is a novel adipokine that links obesity and inflammation.
Topics: Adipocytes; Adipokines; Animals; B-Cell Activating Factor; B-Cell Activation Factor Receptor; Cell Differentiation; Hypoglycemic Agents; Inflammation; Mice; Obesity; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2009 |
IGFBP-3, hypoxia and TNF-alpha inhibit adiponectin transcription.
Topics: 3T3-L1 Cells; Adiponectin; Animals; Cell Hypoxia; Cobalt; Fibroblasts; Genes, Reporter; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Like Growth Factor Binding Protein 3; Mice; Obesity; PPAR gamma; Retinoid X Receptor alpha; Rosiglitazone; Thiazolidinediones; Transcription, Genetic; Tumor Necrosis Factor-alpha | 2009 |
Insulin resistance acts as an independent risk factor exacerbating high-purine diet induced renal injury and knee joint gouty lesions.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Gout; Homeostasis; Hyperuricemia; Hypoglycemic Agents; Insulin Resistance; Knee Joint; Male; Obesity; Organic Anion Transport Protein 1; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Purines; Rats; Rats, Inbred OLETF; Risk Factors; Rosiglitazone; Thiazolidinediones; Uric Acid | 2009 |
CXC ligand 5 is an adipose-tissue derived factor that links obesity to insulin resistance.
Topics: Adipose Tissue; Animals; Chemokine CXCL5; Gene Expression Regulation; Humans; Insulin Resistance; Macrophages; Mice; Obesity; RNA, Messenger; Rosiglitazone; Signal Transduction; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2009 |
Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21.
Topics: Cell Line; Diabetes Mellitus, Type 2; Fasting; Fatty Acids, Nonesterified; Female; Fibroblast Growth Factors; Gene Expression Regulation; Glucose Clamp Technique; Glycerol; Homeostasis; Humans; Hyperinsulinism; Hypoglycemic Agents; Lecithins; Male; Obesity; PPAR alpha; PPAR gamma; Reference Values; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2009 |
Neferine enhances insulin sensitivity in insulin resistant rats.
Topics: Animals; Anti-Obesity Agents; Benzylisoquinolines; Blood Glucose; Female; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Insulin Resistance; Nelumbo; Obesity; Phytotherapy; Plant Extracts; Rats; Rats, Wistar; Rosiglitazone; Seeds; Thiazolidinediones; Triglycerides; Tumor Necrosis Factor-alpha | 2009 |
Functional significance of skeletal muscle adiponectin production, changes in animal models of obesity and diabetes, and regulation by rosiglitazone treatment.
Topics: Adiponectin; Animals; Cells, Cultured; Diabetes Mellitus, Experimental; Disease Models, Animal; Gene Expression Regulation; Hypoglycemic Agents; Insulin; Male; Mice; Mice, Obese; Muscle, Skeletal; Obesity; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones | 2009 |
Proteomic analysis of human adipose tissue after rosiglitazone treatment shows coordinated changes to promote glucose uptake.
Topics: Adipose Tissue; Adult; Blotting, Western; Electrophoresis, Gel, Two-Dimensional; Galectin 1; Gene Expression; Glucose; Glucose Transporter Type 4; Humans; Hypoglycemic Agents; Image Processing, Computer-Assisted; Insulin; Male; Mass Spectrometry; Middle Aged; Obesity; Proteome; Proteomics; Regression Analysis; RNA Processing, Post-Transcriptional; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2010 |
Artemisia capillaris inhibits lipid accumulation in 3T3-L1 adipocytes and obesity in C57BL/6J mice fed a high fat diet.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue; Animals; Artemisia; Carnitine O-Palmitoyltransferase; Cell Line; Diet; Dietary Fats; Disease Models, Animal; Fatty Acids, Nonesterified; Flavonoids; Glycerolphosphate Dehydrogenase; Hypolipidemic Agents; Leptin; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Obesity; Phenols; Phytotherapy; Plant Extracts; PPAR gamma; Rosiglitazone; Thiazolidinediones; Triglycerides | 2009 |
FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats.
Topics: Animals; Chenodeoxycholic Acid; Disease Models, Animal; Drug Therapy, Combination; Fatty Liver; Gene Expression Regulation; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Receptor Substrate Proteins; Insulin Resistance; Lipid Metabolism; Lipids; Liver; Male; Muscle, Skeletal; Obesity; Phosphorylation; Random Allocation; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Time Factors | 2010 |
Complement factor H is expressed in adipose tissue in association with insulin resistance.
Topics: Adipose Tissue; Complement Factor B; Complement Factor H; Diabetes Mellitus, Type 2; Gene Expression Regulation; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Obesity; Omentum; Organ Specificity; Reference Values; Rosiglitazone; Skin; Thiazolidinediones; Weight Loss; White People | 2010 |
Inhibitory effect of evodiamine alone and in combination with rosiglitazone on in vitro adipocyte differentiation and in vivo obesity related to diabetes.
Topics: Adipocytes; Adiponectin; Adipose Tissue; Animals; Blood Glucose; Cell Differentiation; Cell Line; Dietary Fats; Drug Therapy, Combination; Hypoglycemic Agents; Insulin; Liver; Mice; Mice, Inbred C57BL; Obesity; Plant Extracts; Quinazolines; Rosiglitazone; Thiazolidinediones; Weight Gain | 2010 |
Selective effects of PPARgamma agonists and antagonists on human pre-adipocyte differentiation.
Topics: Adipocytes; Adult; Anilides; Cell Differentiation; Cell Line; Cells, Cultured; Female; Gene Expression; Humans; Obesity; PPAR gamma; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2010 |
Rosiglitazone decreases intra- to extramyocellular fat ratio in obese non-diabetic adults with metabolic syndrome.
Topics: Adipose Tissue; Adult; Body Mass Index; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Magnetic Resonance Spectroscopy; Male; Metabolic Syndrome; Obesity; Rosiglitazone; Thiazolidinediones; Triglycerides; Waist-Hip Ratio | 2010 |
Modulation of nutrient sensing nuclear hormone receptors promotes weight loss through appetite suppression in mice.
Topics: Animals; Appetite Depressants; Appetite Regulation; Energy Metabolism; Insulin Resistance; Lipid Peroxidation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Obesity; PPAR alpha; PPAR delta; PPAR gamma; Rosiglitazone; Thiazoles; Thiazolidinediones; Weight Loss | 2010 |
Abscisic acid synergizes with rosiglitazone to improve glucose tolerance and down-modulate macrophage accumulation in adipose tissue: possible action of the cAMP/PKA/PPAR γ axis.
Topics: Abscisic Acid; Adipose Tissue; Animals; Blood Glucose; Cyclic AMP-Dependent Protein Kinases; Data Collection; Diabetes Mellitus; Glucose Intolerance; Inflammation; Insulin; Macrophages; Mice; Mice, Obese; Obesity; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2010 |
Proteasomal degradation of retinoid X receptor alpha reprograms transcriptional activity of PPARgamma in obese mice and humans.
Topics: 3T3-L1 Cells; Adipose Tissue; Animals; Gene Expression Regulation; Humans; Insulin Resistance; Male; Mice; Mice, Obese; Obesity; PPAR gamma; Proteasome Endopeptidase Complex; Retinoid X Receptor alpha; Rosiglitazone; Thiazolidinediones; Transcription, Genetic; Ubiquitin Thiolesterase | 2010 |
Rosiglitazone, thiazolidinediones and atherosclerosis.
Topics: Anti-Inflammatory Agents; Atherosclerosis; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Leukocytes, Mononuclear; Nitric Oxide; Obesity; Reactive Oxygen Species; Rosiglitazone; Thiazolidinediones; Time Factors | 2010 |
Involvement of cholecystokinin in baseline and post-prandial whole body insulin sensitivity in rats.
Topics: Animals; Cholecystokinin; Gene Expression Regulation; Glucose Clamp Technique; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Obesity; Polymerase Chain Reaction; Postprandial Period; Rats; Rats, Inbred OLETF; Rats, Long-Evans; Receptor, Cholecystokinin A; Receptor, Cholecystokinin B; Rosiglitazone; Thiazolidinediones | 2010 |
Obesity: New life for antidiabetic drugs.
Topics: Adipose Tissue; Animals; Cyclin-Dependent Kinase 5; Diabetes Mellitus, Experimental; Dietary Fats; Humans; Insulin; Ligands; Mice; Obesity; Phosphorylation; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2010 |
Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5.
Topics: Adipose Tissue; Amino Acid Sequence; Animals; Cell Line; Cyclin-Dependent Kinase 5; Diabetes Mellitus, Experimental; Dietary Fats; Humans; Insulin; Ligands; Mice; Models, Molecular; Obesity; Phosphorylation; Phosphoserine; PPAR gamma; Protein Conformation; Rosiglitazone; Thiazolidinediones | 2010 |
Effect of glucose and insulin on oxidized low-density lipoprotein phagocytosis by human monocytes: a pilot study.
Topics: Adolescent; Adult; Body Mass Index; Case-Control Studies; Cell Culture Techniques; Female; Glucose; Guanidines; Humans; Hypoglycemic Agents; Insulin; Lipoproteins, LDL; Male; Monocytes; Obesity; Phagocytosis; Pilot Projects; Rosiglitazone; Sulfones; Sweetening Agents; Thiazolidinediones; Young Adult | 2011 |
Effects of metformin on rosiglitazone-induced cardiac hypertrophy in mice.
Topics: Animals; Body Weight; Cardiomegaly; Drug Therapy, Combination; Eating; Male; Metformin; Mice; Mice, Inbred BALB C; Obesity; Rosiglitazone; Thiazolidinediones; Weight Gain | 2010 |
PPARgamma activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice.
Topics: Abdominal Fat; Animals; Anti-Inflammatory Agents; Antigens, Differentiation; Benzimidazoles; Benzoates; CD3 Complex; Chemokine CXCL12; Chemotaxis; Dietary Fats; Disease Models, Animal; Inflammation; Insulin Resistance; Lymphocyte Activation; Macrophages; Male; Mice; Mice, Inbred C57BL; Obesity; PPAR gamma; Rosiglitazone; T-Lymphocytes; Telmisartan; Thiazolidinediones; Time Factors | 2010 |
Lipocalin 2 is a selective modulator of peroxisome proliferator-activated receptor-gamma activation and function in lipid homeostasis and energy expenditure.
Topics: Acute-Phase Proteins; Adipocytes; Adipose Tissue, Brown; Animals; Dietary Fats; Energy Metabolism; Homeostasis; Hypoglycemic Agents; Lipid Metabolism; Lipocalin-2; Lipocalins; Mice; Mice, Inbred C57BL; Mice, Knockout; Obesity; Oncogene Proteins; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2011 |
Remission of diabetes mellitus type 2 with severe hyperglycemia after Exenatide treatment.
Topics: Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Metformin; Middle Aged; Obesity; Peptides; Remission Induction; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Venoms; Weight Loss | 2010 |
Improvement on lipid metabolic disorder by 3'-deoxyadenosine in high-fat-diet-induced fatty mice.
Topics: Animals; Area Under Curve; Cordyceps; Deoxyadenosines; Dietary Fats; Disease Models, Animal; Fenofibrate; Glucose; Glucose Clamp Technique; Glucose Intolerance; Insulin; Insulin Resistance; Lipid Metabolism; Lipid Metabolism Disorders; Male; Mice; Mice, Inbred C57BL; Muscle, Skeletal; Obesity; Phytotherapy; Rosiglitazone; Thiazolidinediones; Weight Gain | 2010 |
Severe HDL-c reduction during rosiglitazone therapy in an obese woman with type 2 diabetes.
Topics: Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Middle Aged; Obesity; Rosiglitazone; Thiazolidinediones | 2010 |
Rosiglitazone, PPARγ, and type 2 diabetes.
Topics: Cyclin-Dependent Kinase 5; Diabetes Mellitus, Type 2; Gene Expression; Hypoglycemic Agents; Obesity; Phosphorylation; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2010 |
Identification of the target proteins of rosiglitazone in 3T3-L1 adipocytes through proteomic analysis of cytosolic and secreted proteins.
Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Animals; Cytoplasm; Cytoskeletal Proteins; Diabetes Mellitus, Type 2; Eukaryotic Translation Initiation Factor 5A; Fatty Acid-Binding Proteins; Gene Expression Profiling; Gene Expression Regulation; Insulin; Mice; Obesity; Peptide Initiation Factors; Proteome; RNA-Binding Proteins; Rosiglitazone; Tandem Mass Spectrometry; Thiazolidinediones | 2011 |
Brain PPAR-γ promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones.
Topics: Aged; Animals; Brain; Diabetes Mellitus, Type 2; Energy Metabolism; Humans; Hypoglycemic Agents; Insulin Resistance; Mice; Mice, Knockout; Middle Aged; Obesity; PPAR gamma; Rosiglitazone; Signal Transduction; Thiazolidinediones; Weight Gain | 2011 |
Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice.
Topics: Animals; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Synergism; Drug Therapy, Combination; Fenofibrate; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Obesity; Rosiglitazone; Thiazolidinediones | 2011 |
Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Diabetic Nephropathies; Disease Models, Animal; Enalapril; Humans; Hypoglycemic Agents; Kidney; Liver; Male; Metabolic Syndrome; Myocardium; Obesity; PPAR gamma; Rats; Rosiglitazone; Thiazolidinediones | 2011 |
Expression and regulation of adipocyte fatty acid binding protein in granulosa cells and its relation with clinical characteristics of polycystic ovary syndrome.
Topics: Adult; Body Mass Index; C-Reactive Protein; Cells, Cultured; Fatty Acid-Binding Proteins; Female; Gene Expression Regulation; Granulosa Cells; Humans; Hypercholesterolemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Obesity; Polycystic Ovary Syndrome; PPAR gamma; RNA, Messenger; Rosiglitazone; Severity of Illness Index; Testosterone; Thiazolidinediones; Up-Regulation | 2011 |
Reactivity of the aorta and mesenteric resistance arteries from the obese spontaneously hypertensive rat: effects of glitazones.
Topics: Animals; Aorta; Blood Pressure; Endothelium, Vascular; Hypoglycemic Agents; In Vitro Techniques; Male; Mesenteric Arteries; Microcirculation; Muscle Contraction; Muscle Relaxation; Muscle, Smooth, Vascular; Obesity; Pioglitazone; Prostaglandins; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rosiglitazone; Superoxides; Thiazolidinediones; Vascular Resistance; Vasoconstrictor Agents | 2011 |
Decreased STAMP2 expression in association with visceral adipose tissue dysfunction.
Topics: Adipocytes; Adult; Aged; Cell Differentiation; Diabetes Mellitus, Type 2; Female; Gene Expression; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Male; Membrane Proteins; Middle Aged; Obesity; Oxidoreductases; Rosiglitazone; Subcutaneous Fat; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2011 |
Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue, White; Animals; Biphenyl Compounds; Body Fluids; Chlorocebus aethiops; COS Cells; Cyclin-Dependent Kinase 5; Dietary Fats; Disease Models, Animal; Dose-Response Relationship, Drug; HEK293 Cells; Humans; Hypoglycemic Agents; Ligands; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Models, Molecular; Obesity; Osteogenesis; Phosphorylation; Phosphoserine; PPAR gamma; Rosiglitazone; Thiazolidinediones; Transcription, Genetic; Tumor Necrosis Factor-alpha; Weight Gain | 2011 |
Metabolic stress-induced inflammation plays a major role in the development of osteoarthritis in mice.
Topics: Animals; Body Weight; C-Reactive Protein; Cytokines; Diet, High-Fat; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Inflammation; Insulin; Male; Mice; Mice, Transgenic; Obesity; Osteoarthritis; Pyrimidines; Rosiglitazone; Rosuvastatin Calcium; Sulfonamides; Thiazolidinediones | 2012 |
Unmasking differential effects of rosiglitazone and pioglitazone in the combination treatment with n-3 fatty acids in mice fed a high-fat diet.
Topics: Animals; Blood Glucose; Dietary Fats; Fatty Acids, Omega-3; Homeostasis; Hypoglycemic Agents; Lipids; Male; Metabolomics; Mice; Mice, Inbred C57BL; Obesity; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2011 |
Activation of protein kinase A and exchange protein directly activated by cAMP promotes adipocyte differentiation of human mesenchymal stem cells.
Topics: 1-Methyl-3-isobutylxanthine; Adipocytes; Adipose Tissue; Animals; Cell Differentiation; Cell Line; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Dexamethasone; Epoprostenol; Gene Expression Profiling; Gene Expression Regulation; Guanine Nucleotide Exchange Factors; Humans; Insulin; Mesenchymal Stem Cells; Mice; Obesity; Rosiglitazone; Signal Transduction; Thiazolidinediones | 2012 |
Early induction of a brown-like phenotype by rosiglitazone in the epicardial adipose tissue of fatty Zucker rats.
Topics: Adipose Tissue, Brown; Animals; Fatty Acids; Gene Expression Regulation; Insulin Resistance; Intra-Abdominal Fat; Lipid Metabolism; Mitochondria, Heart; Obesity; Pericardium; Phenotype; PPAR gamma; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones | 2012 |
Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione.
Topics: 3T3-L1 Cells; Animals; Binding, Competitive; Cells, Cultured; Female; Gene Expression; Glycolysis; Hep G2 Cells; Hepatocytes; Humans; Hypoglycemic Agents; Insulin Resistance; Lipogenesis; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Obese; Molecular Structure; Obesity; Pioglitazone; PPAR gamma; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones | 2012 |
Mitochondrial dysfunction and activation of iNOS are responsible for the palmitate-induced decrease in adiponectin synthesis in 3T3L1 adipocytes.
Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Adipose Tissue; Animals; Endoplasmic Reticulum Stress; Insulin Resistance; Mice; Mitochondria; Mitochondrial Turnover; Nitric Oxide Synthase Type II; Nuclear Respiratory Factor 1; Obesity; Palmitic Acid; Rosiglitazone; Thiazolidinediones | 2012 |
Rosiglitazone improves insulin sensitivity and baroreflex gain in rats with diet-induced obesity.
Topics: Animals; Baroreflex; Diet, High-Fat; Insulin Resistance; Male; Obesity; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Vasodilator Agents | 2012 |
Preservation of metabolic flexibility in skeletal muscle by a combined use of n-3 PUFA and rosiglitazone in dietary obese mice.
Topics: Animals; Diet, High-Fat; Drug Synergism; Fatty Acids, Omega-3; Gene Expression Regulation; Glycolysis; Male; Metabolomics; Mice; Mice, Inbred C57BL; Muscle Fibers, Skeletal; Muscle, Skeletal; Obesity; Oxidation-Reduction; Rosiglitazone; Thiazolidinediones | 2012 |
Negative regulation of adipogenesis by kaempferol, a component of Rhizoma Polygonati falcatum in 3T3-L1 cells.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Animals; Anti-Obesity Agents; Drugs, Chinese Herbal; Homeostasis; Hypoglycemic Agents; Kaempferols; Lipid Metabolism; Lipolysis; Mice; Microarray Analysis; Obesity; Phytotherapy; Polygonatum; PPAR gamma; Reverse Transcriptase Polymerase Chain Reaction; Rhizome; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Transcription Factors; Triglycerides | 2012 |
META060 protects against diet-induced obesity and insulin resistance in a high-fat-diet fed mouse.
Topics: Animals; Body Composition; Diet, High-Fat; Dietary Supplements; Glucose Tolerance Test; Humulus; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Obesity; Phytotherapy; Plant Extracts; Rosiglitazone; Thiazolidinediones | 2013 |
Quantitative histopathological assessment of retardation of islets of langerhans degeneration in rosiglitazone-dosed obese ZDF rats using combined insulin and collagens (I and III) immunohistochemistry with automated image analysis and statistical modelin
Topics: Algorithms; Animals; Collagen Type I; Collagen Type III; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Image Processing, Computer-Assisted; Immunohistochemistry; Insulin; Islets of Langerhans; Male; Models, Statistical; Obesity; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones | 2013 |
Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor γ agonist improve vascular function and decrease renal injury in hypertensive obese rats.
Topics: Albuminuria; Animals; Blood Pressure; Cardiomegaly; Epoxide Hydrolases; Hypertension; Hypoglycemic Agents; Kidney Glomerulus; Macrophages; Male; Obesity; PPAR gamma; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rosiglitazone; Species Specificity; Syndrome; Thiazolidinediones | 2012 |
Weight loss improves the adipogenic capacity of human preadipocytes and modulates their secretory profile.
Topics: Adipocytes; Adipogenesis; Adiponectin; Cells, Cultured; Chemokine CCL2; Cytokines; Enzyme-Linked Immunosorbent Assay; Female; Humans; Interleukin-8; Leptin; Obesity; PPAR gamma; Rosiglitazone; Thiazolidinediones; Weight Loss | 2013 |
Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPARgamma agonists.
Topics: Adipose Tissue; Animals; Fatty Acids, Nonesterified; Female; Insulin; Insulin Receptor Substrate Proteins; Kinetics; Liver; Muscle, Skeletal; Obesity; Phosphoproteins; Phosphorylation; Phosphoserine; Phosphotyrosine; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rats; Rats, Zucker; Receptor, Insulin; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Rosiglitazone treatment restores renal dopamine receptor function in obese Zucker rats.
Topics: Animals; Benzazepines; Binding, Competitive; Blood Glucose; Blood Pressure; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Down-Regulation; Epithelial Cells; Glucose; Hyperinsulinism; Hypoglycemic Agents; Insulin; Kidney; Kidney Tubules, Proximal; Male; Obesity; Rats; Rats, Zucker; Receptors, Dopamine D1; Rosiglitazone; Sodium-Potassium-Exchanging ATPase; Thiazoles; Thiazolidinediones | 2002 |
Intramyocellular lipid and insulin resistance: a longitudinal in vivo 1H-spectroscopic study in Zucker diabetic fatty rats.
Topics: Adipose Tissue; Animals; Diabetes Mellitus; Diabetes Mellitus, Type 2; Insulin Resistance; Lipid Metabolism; Liver; Longitudinal Studies; Magnetic Resonance Spectroscopy; Male; Muscle, Skeletal; Obesity; Organ Size; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation.
Topics: Adipocytes; Animals; Blood Vessels; CCAAT-Enhancer-Binding Protein-beta; Cell Differentiation; Diet; Disease Models, Animal; Gene Expression Regulation, Enzymologic; Hypoglycemic Agents; Male; Matrix Metalloproteinase 12; Matrix Metalloproteinase 2; Matrix Metalloproteinase 3; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Matrix Metalloproteinases, Membrane-Associated; Matrix Metalloproteinases, Secreted; Metalloendopeptidases; Mice; Mice, Inbred AKR; Mice, Inbred C57BL; Mice, Obese; Mitosis; Obesity; Phenylalanine; Protease Inhibitors; RNA, Messenger; Rosiglitazone; Stromal Cells; Thiazoles; Thiazolidinediones; Thiophenes; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-3 | 2003 |
Reduction of intramyocellular lipid following short-term rosiglitazone treatment in Zucker fatty rats: an in vivo nuclear magnetic resonance study.
Topics: Animals; Blood Glucose; Insulin; Lipid Metabolism; Lipids; Magnetic Resonance Spectroscopy; Muscle Fibers, Skeletal; Muscle, Skeletal; Obesity; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides; Weight Gain | 2003 |
[Therapy decision based on the glucose triad. Drug treatment of type 2 diabetes].
Topics: 1-Deoxynojirimycin; Acarbose; Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Glucosamine; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Insulin Resistance; Insulin Secretion; Metformin; Obesity; Pioglitazone; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Time Factors | 2003 |
[When HbA1c cannot be pushed down under 7. Don't hesitate to use a 2d antidiabetic agent].
Topics: Diabetes Mellitus; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Rapid reversal of hepatic steatosis, and reduction of muscle triglyceride, by rosiglitazone: MRI/S studies in Zucker fatty rats.
Topics: Animals; Fatty Liver; Hepatomegaly; Hypoglycemic Agents; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Muscle, Skeletal; Obesity; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 2003 |
Effect of rosiglitazone on the differential expression of obesity and insulin resistance associated proteins in lep/lep mice.
Topics: Animals; Electrophoresis, Gel, Two-Dimensional; Hypoglycemic Agents; Insulin Resistance; Leptin; Mice; Mice, Inbred C57BL; Obesity; Rosiglitazone; Thiazolidinediones | 2003 |
Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation.
Topics: Adipose Tissue; Animals; Basal Metabolism; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids; Fenofibrate; Glycogen; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Islets of Langerhans; Male; Muscle, Skeletal; Obesity; Rats; Rats, Inbred OLETF; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides; Viscera | 2003 |
Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance.
Topics: Adipocytes; Adipose Tissue; Animals; Body Weight; Cells, Cultured; Down-Regulation; Gene Expression Regulation; Giant Cells; Immunohistochemistry; In Situ Hybridization; Inflammation; Insulin Resistance; Lymphocytes; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Models, Biological; Neutrophils; Obesity; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Time Factors; Up-Regulation | 2003 |
Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease.
Topics: Anastomosis, Surgical; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Duodenum; Eating; Follow-Up Studies; Gastric Bypass; Glucose Tolerance Test; Jejunum; Male; Obesity; Probability; Random Allocation; Rats; Rats, Inbred Strains; Reference Values; Rosiglitazone; Thiazolidinediones; Weight Loss | 2004 |
Rosiglitazone restores G-protein coupling, recruitment, and function of renal dopamine D1A receptor in obese Zucker rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Blood Glucose; Cell Membrane; Colforsin; Dopamine; Heterotrimeric GTP-Binding Proteins; Insulin; Insulin Resistance; Kidney Tubules, Proximal; Male; Obesity; Protein Transport; Rats; Rats, Zucker; Receptors, Dopamine D1; Rosiglitazone; Sodium; Thiazolidinediones; Urine | 2004 |
[An overweight diabetic does not tolerate metformin. Insulin sensitizer can be prescribed alone, too].
Topics: Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Obesity; Placebos; Risk Factors; Rosiglitazone; Thiazolidinediones; Time Factors | 2003 |
Visceral obesity without insulin resistance in late-onset obesity rats.
Topics: Absorption; Animals; Animals, Genetically Modified; Body Temperature; Diet; Dietary Fats; Disease Susceptibility; Eating; Estradiol; Female; Glucose; Growth Hormone; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Obesity; Ovariectomy; Phenotype; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Time Factors; Viscera | 2004 |
Increased adipose tissue expression of Grb14 in several models of insulin resistance.
Topics: 3T3 Cells; Adaptor Proteins, Signal Transducing; Adipocytes; Adipose Tissue; Animals; Carrier Proteins; Diabetes Mellitus, Type 2; Disease Models, Animal; Fasting; Gene Expression Regulation; Insulin; Insulin Resistance; Liver; Metformin; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Muscles; Obesity; Proteins; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2004 |
Effects of PPARgamma and PPARalpha agonists on serum leptin levels in diet-induced obese rats.
Topics: Adipose Tissue; Animals; Dietary Fats; Energy Metabolism; Gemfibrozil; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Leptin; Male; Obesity; PPAR alpha; PPAR gamma; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Weight Gain | 2004 |
Lipin expression preceding peroxisome proliferator-activated receptor-gamma is critical for adipogenesis in vivo and in vitro.
Topics: 3T3 Cells; Adipocytes; Adipose Tissue; Animals; CCAAT-Enhancer-Binding Protein-alpha; Cell Differentiation; Diet; Dietary Fats; Gene Expression Regulation; Hypoglycemic Agents; Lipid Metabolism; Lipodystrophy; Male; Mice; Mice, Inbred BALB C; Nuclear Proteins; Obesity; Phosphatidate Phosphatase; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Transcription Factors | 2004 |
Rosiglitazone enhances glucose tolerance by mechanisms other than reduction of fatty acid accumulation within skeletal muscle.
Topics: Animals; Diglycerides; Fatty Acids; Female; Glucose Intolerance; Hypoglycemic Agents; Muscle, Skeletal; Obesity; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones; Triglycerides | 2004 |
Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance.
Topics: Androgens; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Luteinizing Hormone; Obesity; Ovary; Polycystic Ovary Syndrome; Rosiglitazone; Thiazolidinediones | 2005 |
Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue; Animals; Blood Glucose; Blotting, Northern; Blotting, Western; Chaperonin 60; Fatty Acids; Insulin; Mass Spectrometry; Mice; Mice, Inbred C57BL; Mice, Obese; Mice, Transgenic; Microscopy, Fluorescence; Mitochondria; Obesity; Oligonucleotide Array Sequence Analysis; Oxygen; Palmitic Acid; PPAR gamma; RNA, Complementary; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Time Factors; Vasodilator Agents | 2004 |
Revised vs original QUICKI index during diet + rosiglitazone treatment in obese subjects.
Topics: Body Mass Index; Diet, Reducing; Humans; Hypoglycemic Agents; Insulin Resistance; Monitoring, Physiologic; Obesity; Rosiglitazone; Thiazolidinediones; Weight Loss | 2004 |
Gene expression and adiposity are modified by soy protein in male Zucker diabetic fatty rats.
Topics: Adipose Tissue; Animals; Body Composition; Caseins; Diabetes Mellitus; Diet; Dietary Proteins; Gene Expression; Hypoglycemic Agents; Isoflavones; Lipids; Liver; Male; Obesity; Organ Size; Polymerase Chain Reaction; Rats; Rats, Zucker; RNA, Messenger; Rosiglitazone; Soybean Proteins; Thiazolidinediones | 2004 |
Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Drinking; Drug Therapy, Combination; Drug Tolerance; Eating; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Islets of Langerhans; Male; Obesity; Pentanoic Acids; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Time Factors | 2005 |
Divergent effects of rosiglitazone on protein-mediated fatty acid uptake in adipose and in muscle tissues of Zucker rats.
Topics: Adipocytes; Adipose Tissue; Animals; CD36 Antigens; Cell Membrane; Fatty Acid Transport Proteins; Fatty Acids; Female; Hypoglycemic Agents; Membrane Transport Proteins; Muscle, Skeletal; Muscles; Obesity; Palmitic Acid; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones; Triglycerides | 2005 |
Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes.
Topics: 3T3 Cells; Adipocytes; Animals; Biotransformation; Blood Glucose; Cell Differentiation; Cholic Acids; Diabetes Mellitus, Type 2; Dogs; Drug Synergism; Estrone; Glucocorticoids; Glucose; Glutamate-Ammonia Ligase; Hypoglycemic Agents; Liver; Male; Mice; Obesity; Prednisolone; Rats; Rats, Zucker; Receptors, Glucocorticoid; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones; Tyrosine Transaminase | 2005 |
S-nitrosation of the insulin receptor, insulin receptor substrate 1, and protein kinase B/Akt: a novel mechanism of insulin resistance.
Topics: Animals; Glutathione; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; Mice; Mice, Inbred NOD; Muscle, Skeletal; Nitric Oxide; Nitro Compounds; Nitrosation; Obesity; Phosphoproteins; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Receptor, Insulin; Rosiglitazone; Thiazolidinediones | 2005 |
Rosiglitazone restores renal D1A receptor-Gs protein coupling by reducing receptor hyperphosphorylation in obese rats.
Topics: Animals; beta-Adrenergic Receptor Kinases; Blood Glucose; Blood Pressure; Body Weight; Cell Membrane; Cyclic AMP-Dependent Protein Kinases; G-Protein-Coupled Receptor Kinase 4; GTP-Binding Protein alpha Subunits, Gs; Immunoprecipitation; Insulin; Insulin Resistance; Kidney Tubules, Proximal; Male; Obesity; Phosphorylation; Protein Serine-Threonine Kinases; Rats; Rats, Zucker; Receptors, Dopamine D1; Receptors, G-Protein-Coupled; Rosiglitazone; Thiazolidinediones | 2005 |
Regulation of the renal thiazide-sensitive Na-Cl cotransporter, blood pressure, and natriuresis in obese Zucker rats treated with rosiglitazone.
Topics: Aging; Animals; Blood Glucose; Blood Pressure; Body Weight; Glucose Tolerance Test; Hypoglycemic Agents; Immunoblotting; Immunoenzyme Techniques; Kidney; Male; Natriuresis; Obesity; PPAR gamma; Proteinuria; Rats; Rats, Zucker; Receptors, Drug; Rosiglitazone; Sodium Chloride; Sodium Chloride Symporters; Solute Carrier Family 12, Member 3; Symporters; Telemetry; Thiazolidinediones; Tissue Distribution | 2005 |
Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone.
Topics: Adipocytes; Angiotensin II; Antihypertensive Agents; Cells, Cultured; Drug Antagonism; Humans; Insulin; Obesity; Renin-Angiotensin System; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha; Up-Regulation | 2005 |
Free fatty acid-induced insulin resistance in the obese is not prevented by rosiglitazone treatment.
Topics: Adult; C-Reactive Protein; Drug Combinations; Emulsions; Fatty Acids, Nonesterified; Female; Glucose Clamp Technique; Heparin; Humans; Infusion Pumps; Insulin Resistance; Male; Middle Aged; Obesity; Rosiglitazone; Serum Amyloid A Protein; Thiazolidinediones; Triglycerides | 2005 |
Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes.
Topics: Adipose Tissue; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Gene Expression Regulation; Glucose Transporter Type 4; Hepatocytes; Insulin; Insulin Resistance; Liver; Mice; Mice, Knockout; Monosaccharide Transport Proteins; Muscle Proteins; Muscles; Obesity; Oligonucleotide Array Sequence Analysis; Phosphoenolpyruvate Carboxykinase (GTP); Retinol-Binding Proteins; Retinol-Binding Proteins, Plasma; Rosiglitazone; Signal Transduction; Thiazolidinediones | 2005 |
Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individuals.
Topics: Adult; Blood Glucose; Body Mass Index; C-Peptide; Female; Glucose; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Male; Metabolic Clearance Rate; Middle Aged; Obesity; Rosiglitazone; Thiazolidinediones | 2005 |
Chronic rosiglitazone treatment restores AMPKalpha2 activity in insulin-resistant rat skeletal muscle.
Topics: AMP-Activated Protein Kinases; Animals; Cell Line; Dose-Response Relationship, Drug; Enzyme Activation; Female; Hypoglycemic Agents; Insulin Resistance; Multienzyme Complexes; Muscle Fibers, Skeletal; Muscle, Skeletal; Obesity; Protein Serine-Threonine Kinases; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones | 2006 |
Increased A-ring reduction of glucocorticoids in obese Zucker rats: effects of insulin sensitization.
Topics: Animals; Cholestenone 5 alpha-Reductase; Glucocorticoids; Hypoglycemic Agents; Insulin; Liver; Metformin; Obesity; Oxidoreductases; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones | 2005 |
PPAR-gamma response element activity in intact primary human adipocytes: effects of fatty acids.
Topics: Adipocytes; Cells, Cultured; Diabetes Mellitus, Type 2; Fatty Acid Transport Proteins; Fatty Acids; Female; Gene Expression Regulation; Humans; Hypoglycemic Agents; Luciferases; Middle Aged; Obesity; PPAR gamma; Rosiglitazone; Thiazolidinediones; Transfection | 2006 |
Differential endocrine responses to rosiglitazone therapy in new mouse models of type 2 diabetes.
Topics: Adiponectin; Analysis of Variance; Animals; Biomarkers; Diabetes Mellitus, Type 2; Disease Models, Animal; Fatty Liver; Female; Glucose Intolerance; Hypoglycemic Agents; Insulin; Leptin; Male; Mice; Mice, Congenic; Mice, Inbred NOD; Mice, Obese; Obesity; Phenotype; Plasminogen Activator Inhibitor 1; Quantitative Trait, Heritable; Recombination, Genetic; Resistin; Rosiglitazone; Species Specificity; Syndrome; Thiazolidinediones | 2006 |
Biological characterization of a heterodimer-selective retinoid X receptor modulator: potential benefits for the treatment of type 2 diabetes.
Topics: Analysis of Variance; Animals; Apolipoprotein A-I; Area Under Curve; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Interactions; Fatty Acids, Unsaturated; Female; Hypoglycemic Agents; Mice; Mice, Transgenic; Obesity; Phenyl Ethers; PPAR gamma; Rats; Rats, Sprague-Dawley; Rats, Zucker; Retinoid X Receptors; Rosiglitazone; Statistics, Nonparametric; Thiazolidinediones; Thyroid Gland; Triglycerides | 2006 |
Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination.
Topics: Animals; Blood Glucose; Epididymis; Glucose Tolerance Test; Hypoglycemic Agents; Inflammation; Insulin Resistance; Male; Mice; Mice, Inbred Strains; Obesity; Polymerase Chain Reaction; PPAR alpha; PPAR gamma; Pyrimidines; Receptors, Adiponectin; Receptors, Cell Surface; Rosiglitazone; Thiazolidinediones | 2005 |
(+)-Z-Bisdehydrodoisynolic acid ameliorates obesity and the metabolic syndrome in female ZDF rats.
Topics: Animals; Blood Glucose; Body Weight; Cholesterol; Coronary Vessels; Diabetes Mellitus, Experimental; Disease Models, Animal; Female; Gene Expression; Hypoglycemic Agents; Kidney; Liver; Metabolic Syndrome; Obesity; Organ Size; Phenanthrenes; PPAR alpha; PPAR gamma; Random Allocation; Rats; Rats, Zucker; Risk Factors; Rosiglitazone; Selective Estrogen Receptor Modulators; Thiazolidinediones; Triglycerides | 2005 |
Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice.
Topics: Adiponectin; Animals; Blood Glucose; Corticosterone; Diabetes Mellitus, Type 2; Diet; Female; Glycine; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Liver; Mice; Obesity; Oxazoles; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Thiazolidinediones | 2006 |
Reduced skeletal muscle uncoupling protein-3 content in prediabetic subjects and type 2 diabetic patients: restoration by rosiglitazone treatment.
Topics: Aged; Blood Glucose; Carrier Proteins; Diabetes Mellitus, Type 2; Glucose Clamp Technique; Glucose Intolerance; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Ion Channels; Male; Middle Aged; Mitochondrial Proteins; Muscle, Skeletal; Obesity; Prediabetic State; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Uncoupling Protein 3 | 2006 |
The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome.
Topics: Adult; Androgens; Blood Glucose; Body Mass Index; Fasting; Female; Follicle Stimulating Hormone; Glucose Tolerance Test; Hirsutism; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Luteinizing Hormone; Menstrual Cycle; Menstruation; Metformin; Obesity; Polycystic Ovary Syndrome; Rosiglitazone; Thiazolidinediones; Thinness | 2005 |
The effect of rosiglitazone on overweight subjects with type 1 diabetes.
Topics: Blood Pressure; Diabetes Mellitus, Type 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Obesity; Rosiglitazone; Thiazolidinediones; Waist-Hip Ratio | 2006 |
Optimal treatments for the metabolic syndrome.
Topics: Anti-Obesity Agents; Cardiovascular Diseases; Complementary Therapies; Diabetes Mellitus; Diet; Health Behavior; Humans; Hypoglycemic Agents; Life Style; Metabolic Syndrome; Metformin; Obesity; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Rosiglitazone; Thiazolidinediones | 2006 |
Apolipoprotein AV does not contribute to hypertriglyceridaemia or triglyceride lowering by dietary fish oil and rosiglitazone in obese Zucker rats.
Topics: Animals; Apolipoprotein A-V; Apolipoproteins; Base Sequence; Cholesterol; Dietary Fats; Fatty Acids, Nonesterified; Fatty Acids, Omega-3; Fish Oils; Hypertriglyceridemia; Insulin; Molecular Sequence Data; Obesity; PPAR gamma; Rats; Rats, Zucker; RNA, Messenger; Rosiglitazone; Sequence Alignment; Sequence Homology, Nucleic Acid; Thiazolidinediones; Triglycerides | 2006 |
Reactive oxygen species have a causal role in multiple forms of insulin resistance.
Topics: 3T3-L1 Cells; Animals; Antioxidants; Body Weight; Catalase; Glucose Tolerance Test; Insulin Resistance; Male; Metalloporphyrins; Mice; Mice, Obese; Obesity; Oxidation-Reduction; Reactive Oxygen Species; Rosiglitazone; Superoxide Dismutase; Thiazolidinediones; Transgenes | 2006 |
Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPARgamma agonist's effects on edema and weight gain.
Topics: Adipose Tissue; Animals; Capillary Permeability; Diabetes Mellitus; Edema; Enzyme Activation; Enzyme Inhibitors; Hypoglycemic Agents; Indoles; Male; Maleimides; Mice; Mice, Knockout; Obesity; PPAR gamma; Protein Kinase C; Protein Kinase C beta; Rats; Rats, Zucker; Receptor, Insulin; Rosiglitazone; Thiazolidinediones; Vascular Endothelial Growth Factor A; Weight Gain | 2006 |
A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3T3 Cells; Adipocytes; Animals; Benzimidazoles; Cell Differentiation; Chlorocebus aethiops; Collagen; Cyclic Nucleotide Phosphodiesterases, Type 3; Gels; Gene Expression; Hypoglycemic Agents; Insulin Resistance; Mice; Obesity; Pioglitazone; Plasmids; PPAR gamma; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Triglycerides | 2006 |
Antagonism of peroxisome proliferator-activated receptor gamma prevents high-fat diet-induced obesity in vivo.
Topics: 3T3-L1 Cells; Adipocytes; Anilides; Animals; Binding, Competitive; Body Weight; Dietary Carbohydrates; Dietary Fats; Disease Models, Animal; Glucose Tolerance Test; Hepatocytes; Male; Mice; Mice, Inbred C57BL; Obesity; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2006 |
Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications.
Topics: Adipocytes; Adipose Tissue; Animals; Biomarkers; Cardiovascular Diseases; Cell Line; Clinical Trials as Topic; Cross-Sectional Studies; Cytokines; Dose-Response Relationship, Drug; Female; Humans; Hypoglycemic Agents; Inflammation; Lipolysis; Male; Mice; Mice, Inbred C57BL; Middle Aged; Obesity; Risk Factors; RNA, Messenger; Rosiglitazone; Serum Amyloid A Protein; Stromal Cells; Thiazolidinediones | 2006 |
The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats.
Topics: Adipose Tissue; Animals; Blood Glucose; Carbazoles; Disease Models, Animal; Dyslipidemias; Gene Expression; Gluconeogenesis; Hypoglycemic Agents; Insulin Resistance; Lipids; Liver; Liver Glycogen; Muscles; Obesity; Pancreas; Pioglitazone; PPAR alpha; PPAR gamma; Propionates; Pyrimidines; Rats; Rats, Wistar; Rosiglitazone; Sodium Glutamate; Thiazolidinediones | 2006 |
Rosiglitazone regulates ENaC and Na-K-2Cl cotransporter (NKCC2) abundance in the obese Zucker rat.
Topics: Animals; Diabetes Mellitus, Type 2; Epithelial Sodium Channels; Gene Expression Regulation; Kidney; Male; Obesity; Random Allocation; Rats; Rats, Zucker; Rosiglitazone; Sodium-Potassium-Chloride Symporters; Solute Carrier Family 12, Member 1; Thiazolidinediones; Tissue Distribution | 2006 |
Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists.
Topics: 3T3-L1 Cells; Adipogenesis; Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Chlorocebus aethiops; Dose-Response Relationship, Drug; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Mice; Mice, Obese; Obesity; PPAR gamma; Promoter Regions, Genetic; Recombinant Proteins; Rosiglitazone; Structure-Activity Relationship; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Transfection | 2006 |
Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics.
Topics: Adiponectin; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fatty Acids, Nonesterified; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Leukocyte Count; Male; Matrix Metalloproteinase 9; Middle Aged; Obesity; Resistin; Rosiglitazone; Serum Amyloid A Protein; Thiazolidinediones | 2006 |
Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects.
Topics: Acetyl-CoA Carboxylase; Acyl Coenzyme A; Adult; AMP-Activated Protein Kinases; Carboxy-Lyases; Diabetes Mellitus, Type 2; Fatty Acid Transport Proteins; Fatty Acids; Female; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Malonyl Coenzyme A; Middle Aged; Mitochondria, Muscle; Multienzyme Complexes; Muscle, Skeletal; Obesity; Oxidation-Reduction; Protein Serine-Threonine Kinases; Rosiglitazone; Thiazolidinediones; Triglycerides | 2006 |
JTP-426467 acts as a selective antagonist for peroxisome proliferator-activated receptor gamma in vitro and in vivo.
Topics: Adipocytes; Adipogenesis; Animals; Anti-Obesity Agents; Benzoxazoles; Blood Glucose; Cell Differentiation; Cells, Cultured; Dose-Response Relationship, Drug; Gene Expression Regulation; Genes, Reporter; HeLa Cells; Humans; Hypoglycemic Agents; Leptin; Male; Mice; Obesity; PPAR gamma; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Weight Gain | 2006 |
Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans.
Topics: Acute-Phase Proteins; Adult; Age Factors; Aged; Animals; Biomarkers; Body Mass Index; C-Reactive Protein; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Female; Humans; Hyperglycemia; Inflammation; Insulin Resistance; Lipocalin-2; Lipocalins; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Middle Aged; Obesity; Oncogene Proteins; Polymerase Chain Reaction; PPAR gamma; Proto-Oncogene Proteins; Rosiglitazone; Sex Factors; Thiazolidinediones | 2007 |
Peroxisome proliferator activated receptor gamma activity is low in mature primary human visceral adipocytes.
Topics: Adipocytes; Adult; Aged; Aged, 80 and over; Animals; Disease Models, Animal; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Intra-Abdominal Fat; Luciferases, Firefly; Male; Mice; Mice, Inbred Strains; Middle Aged; Obesity; PPAR gamma; Rosiglitazone; Subcutaneous Fat; Thiazolidinediones; Transfection | 2007 |
Lipocalins and insulin resistance: etiological role of retinol-binding protein 4 and lipocalin-2?
Topics: Acute-Phase Proteins; Adipose Tissue; Animals; Body Mass Index; C-Reactive Protein; Humans; Inflammation; Insulin Resistance; Lipocalin-2; Lipocalins; Liver; Mice; Mice, Obese; Obesity; Oncogene Proteins; PPAR gamma; Proto-Oncogene Proteins; Retinol-Binding Proteins; Retinol-Binding Proteins, Plasma; Rosiglitazone; Thiazolidinediones | 2007 |
Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice.
Topics: Adipocytes; Adiponectin; Adipose Tissue; Adiposity; Animals; Apoptosis; Body Weight; Dietary Fats; Disease Models, Animal; Drug Therapy, Combination; Fatty Liver; Hypoglycemic Agents; Insulin Resistance; Intracellular Signaling Peptides and Proteins; Leptin; Linoleic Acids, Conjugated; Lipid Metabolism; Lipoproteins, VLDL; Liver; Macrophages; Male; Mice; Mice, Inbred C57BL; Obesity; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Time Factors; Triglycerides | 2007 |
Soy protein and isoflavones influence adiposity and development of metabolic syndrome in the obese male ZDF rat.
Topics: Adiposity; Animals; Blood Glucose; Caseins; Hypoglycemic Agents; Isoflavones; Kidney Diseases; Liver; Male; Metabolic Syndrome; Milk Proteins; Obesity; Proteinuria; Rats; Rats, Inbred Strains; Rosiglitazone; Soybean Proteins; Thiazolidinediones | 2007 |
Mechanism by which a novel non-thiazolidinedione peroxisome proliferator-activated receptor gamma agonist, FK614, ameliorates insulin resistance in Zucker fatty rats.
Topics: Acyl-CoA Oxidase; Adipocytes, White; Adipose Tissue; Administration, Oral; Animals; Benzimidazoles; Biological Transport; Cell Count; Cell Size; Epididymis; Fatty Acid-Binding Proteins; Gene Expression; Glucose; Glucose Tolerance Test; Hypoglycemic Agents; Insulin Resistance; Male; Muscle, Skeletal; Obesity; Pioglitazone; PPAR gamma; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones | 2007 |
Metabolic syndrome: a work in progress, but a useful construct.
Topics: Abdominal Fat; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Cohort Studies; Coronary Disease; Diabetes Mellitus, Type 2; Humans; Hypertension; Insulin Resistance; Metabolic Syndrome; Models, Biological; Obesity; Prognosis; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
Adipose mitochondrial biogenesis is suppressed in db/db and high-fat diet-fed mice and improved by rosiglitazone.
Topics: Adipose Tissue; Animals; Diabetes Mellitus, Type 2; Dietary Fats; Disease Models, Animal; Gene Expression; Gene Expression Profiling; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Mitochondria; Obesity; PPAR gamma; Rosiglitazone; Thiazolidinediones; Transcription, Genetic | 2007 |
Preventing diabetes, Part II: an action plan.
Topics: Diabetes Mellitus; Diet; Exercise; Humans; Hypoglycemic Agents; Life Style; Metformin; Obesity; Rosiglitazone; Smoking; Thiazolidinediones; Weight Loss | 2007 |
The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms.
Topics: Adipocytes; Adipose Tissue; Adult; Body Mass Index; Calcium; Cannabinoid Receptor Modulators; Cell Differentiation; Female; Glucose; Humans; Hypoglycemic Agents; Male; Microscopy, Confocal; Obesity; Phosphatidylinositol 3-Kinases; PPAR gamma; Protein Transport; Reverse Transcriptase Polymerase Chain Reaction; RNA; Rosiglitazone; Thiazolidinediones | 2007 |
Essential role of mitochondrial function in adiponectin synthesis in adipocytes.
Topics: Adipocytes; Adiponectin; Adipose Tissue; Animals; Diabetes Mellitus, Type 2; DNA, Mitochondrial; Endoplasmic Reticulum; Epididymis; Fatty Acids, Nonesterified; Gene Expression Regulation; Male; Mice; Mice, Obese; Mitochondria; Obesity; Oxygen Consumption; RNA, Messenger; Rosiglitazone; Stress, Physiological; Thiazolidinediones | 2007 |
Weight gain may contribute to increased fracture risk in women treated with rosiglitazone.
Topics: Animals; Diabetes Complications; Female; Fractures, Bone; Humans; Mice; Middle Aged; Obesity; Rats; Rosiglitazone; Thiazolidinediones | 2007 |
The peroxisome proliferator activated receptor gamma (PPARgamma) ligand rosiglitazone modulates bronchoalveolar lavage levels of leptin, adiponectin, and inflammatory cytokines in lean and obese mice.
Topics: Adiponectin; Animals; Biomarkers; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Cytokines; Disease Models, Animal; Hypoglycemic Agents; Leptin; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; PPAR gamma; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2007 |
Avandia in perspective.
Topics: Blood Glucose; Diabetes Mellitus; Exercise; Health Behavior; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Infarction; Obesity; Risk-Taking; Rosiglitazone; Thiazolidinediones; United States | 2007 |
Effect of metformin and rosiglitazone in a prepubertal boy with Alström syndrome.
Topics: Abnormalities, Multiple; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Obesity; Rosiglitazone; Syndrome; Thiazolidinediones | 2007 |
[Vascular dysfunction in metabolic disorders: evaluation of some therapeutic interventions].
Topics: Adolescent; Adult; Capillary Permeability; Case-Control Studies; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metformin; Microcirculation; Microscopic Angioscopy; Obesity; Plethysmography; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Vasodilator Agents | 2007 |
Energy restriction enhances therapeutic efficacy of the PPARgamma agonist, rosiglitazone, through regulation of visceral fat gene expression.
Topics: Animals; Energy Intake; Gene Expression; Hypoglycemic Agents; Insulin Resistance; Intra-Abdominal Fat; Male; Obesity; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones | 2008 |
Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reverses the adverse effects of diet-induced obesity on oocyte quality.
Topics: Animals; Blastomeres; Cell Differentiation; Cells, Cultured; Cytoprotection; Diet; Diet, Atherogenic; Embryo Culture Techniques; Embryo, Mammalian; Embryonic Development; Female; Gene Expression Regulation; Hypoglycemic Agents; Mice; Mice, Inbred C57BL; Obesity; Oocytes; Ovary; Ovulation; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2008 |
Insulin resistance and impaired functional vasodilation in obese Zucker rats.
Topics: Animals; Antioxidants; Arachidonic Acid; Arterioles; Blood Glucose; Bridged Bicyclo Compounds, Heterocyclic; Cyclic N-Oxides; Disease Models, Animal; Electric Stimulation; Fatty Acids, Unsaturated; Hydrazines; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin Resistance; Kidney Cortex; Male; Muscle, Skeletal; NADPH Oxidases; Obesity; Oxidative Stress; Rats; Rats, Zucker; Receptors, Thromboxane; Rosiglitazone; Spin Labels; Superoxides; Thiazolidinediones; Thromboxanes; Time Factors; Triglycerides; Vasoconstriction; Vasodilation | 2008 |
Re: "Effect of metformin and rosiglitazone in a prepubertal boy with Alström syndrome", Sinha SK et al., JPEM 2007; 20: 1045-1052.
Topics: Child; Deafness; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Male; Metformin; Nystagmus, Congenital; Obesity; Retinitis Pigmentosa; Rosiglitazone; Syndrome; Thiazolidinediones | 2008 |
The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
Topics: Animals; Dietary Fats; Disease Models, Animal; Fatty Acids; Fatty Liver; Fenofibrate; Gene Expression; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Obesity; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2008 |
Obese mice lacking inducible nitric oxide synthase are sensitized to the metabolic actions of peroxisome proliferator-activated receptor-gamma agonism.
Topics: 3T3-L1 Cells; Adiponectin; Adipose Tissue; Animals; Blood Glucose; Blotting, Western; Body Weight; Dietary Fats; Female; Genotype; Glucose Tolerance Test; Insulin; Insulin Resistance; Lipids; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle, Skeletal; Nitric Oxide Synthase Type II; Obesity; Phosphorylation; PPAR gamma; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones | 2008 |
Treatment options in insulin resistance obesity-related acanthosis nigricans.
Topics: Acanthosis Nigricans; Adolescent; Adult; Calcitriol; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity; Octreotide; Retinoids; Rosiglitazone; Thiazolidinediones; Vitamin D | 2008 |
Impact of increased PPARgamma activity in adipocytes in vivo on adiposity, insulin sensitivity and the effects of rosiglitazone treatment.
Topics: Adipocytes; Adipose Tissue, White; Animals; Dietary Fats; Insulin Resistance; Male; Mice; Mice, Transgenic; Obesity; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2008 |
Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes.
Topics: 3T3 Cells; Adipocytes; Animals; Base Sequence; Gene Expression Regulation; Hypoglycemic Agents; Leptin; Mice; Molecular Sequence Data; Obesity; Oligodeoxyribonucleotides; Protein Binding; Proteins; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 1996 |
Effect of the thiazolidinedione BRL49653 and genetic obesity on hepatic gene expression in the Zucker rat.
Topics: Animals; Cell Line; Gene Expression; Hypoglycemic Agents; Liver; Obesity; Phosphoenolpyruvate Carboxykinase (GTP); Rats; Rats, Zucker; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones | 1995 |
Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists.
Topics: Animals; Bexarotene; Blood Glucose; Cells, Cultured; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Insulin Resistance; Ligands; Mice; Mice, Inbred C57BL; Mice, Obese; Nicotinic Acids; Obesity; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Rosiglitazone; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors; Transfection | 1997 |
Novel benzoxazole 2,4-thiazolidinediones as potent hypoglycemic agents. Synthesis and structure-activity relationships.
Topics: Animals; Benzopyrans; Benzoxazoles; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Male; Mice; Obesity; Pioglitazone; Rosiglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats.
Topics: Acetylglucosaminidase; Albuminuria; Animals; Blood Pressure; Body Weight; Histocytochemistry; Hypoglycemic Agents; Immunohistochemistry; Islets of Langerhans; Kidney; Kidney Diseases; Male; Obesity; Pancreas; Pancreatic Diseases; Proteinuria; Rats; Rats, Zucker; Rosiglitazone; Systole; Thiazoles; Thiazolidinediones | 1998 |
A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats.
Topics: Acyl-CoA Oxidase; Adipose Tissue; Animals; Blood Glucose; Body Weight; Carrier Proteins; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fatty Acids; Gene Expression; Hypoglycemic Agents; Insulin; Ligands; Lipid Metabolism; Liver; Male; Myelin P2 Protein; Neoplasm Proteins; Nerve Tissue Proteins; Obesity; Organ Size; Oxidoreductases; Radioligand Assay; Rats; Rats, Wistar; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Transcription Factors; Transcriptional Activation; Triglycerides | 1998 |
The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats.
Topics: Acetylcholine; Animals; Blood Pressure; Endothelium, Vascular; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Obesity; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Vascular Resistance; Vasodilator Agents | 1999 |
Rosiglitazone (BRL49653), a PPARgamma-selective agonist, causes peroxisome proliferator-like liver effects in obese mice.
Topics: Animals; Electrophoresis, Gel, Two-Dimensional; Hypoglycemic Agents; Liver; Male; Mice; Mice, Obese; Obesity; Peroxisome Proliferators; Pyrimidines; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 1999 |
Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes.
Topics: Adipocytes; Adipose Tissue; Adult; Aged; DNA-Binding Proteins; Female; Gene Expression Regulation; Glucose Transporter Type 4; Humans; Hypoglycemic Agents; Ion Channels; Leptin; Male; Membrane Transport Proteins; Middle Aged; Mitochondrial Proteins; Monosaccharide Transport Proteins; Muscle Proteins; Obesity; Phosphatidylinositol 3-Kinases; Proteins; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Thinness; Transcription Factors; Transcription, Genetic; Uncoupling Protein 2 | 1999 |
Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution.
Topics: Animals; Body Weight; Diet; Disease Models, Animal; Dose-Response Relationship, Drug; Eating; Hemodilution; Hemodynamics; Hypoglycemic Agents; Insulin; Leptin; Male; Obesity; Rats; Rats, Wistar; Rosiglitazone; Thiazoles; Thiazolidinediones | 1999 |
Down-regulation of orexin gene expression by severe obesity in the rats: studies in Zucker fatty and zucker diabetic fatty rats and effects of rosiglitazone.
Topics: Animals; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Gene Expression Regulation; Hyperglycemia; Hypoglycemic Agents; Hypothalamus; Insulin; Intracellular Signaling Peptides and Proteins; Leptin; Neuropeptides; Obesity; Orexins; Protein Precursors; Rats; Rats, Zucker; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Thinness; Transcription, Genetic | 2000 |
v- and t-SNARE protein expression in models of insulin resistance: normalization of glycemia by rosiglitazone treatment corrects overexpression of cellubrevin, vesicle-associated membrane protein-2, and syntaxin 4 in skeletal muscle of Zucker diabetic fat
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gene Expression; Glucose Transporter Type 4; Hypoglycemic Agents; Immunoblotting; Insulin Resistance; Male; Membrane Proteins; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Obesity; Qa-SNARE Proteins; R-SNARE Proteins; Rats; Rats, Sprague-Dawley; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Vesicle-Associated Membrane Protein 3 | 2000 |
Retinoid X receptor agonists have anti-obesity effects and improve insulin sensitivity in Zucker fa/fa rats.
Topics: Analysis of Variance; Animals; Blood Glucose; Body Weight; Eating; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Nicotinic Acids; Obesity; Rats; Rats, Zucker; Receptors, Retinoic Acid; Retinoid X Receptors; Rosiglitazone; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors | 2000 |
Mechanisms of dysregulation of 11 beta-hydroxysteroid dehydrogenase type 1 in obese Zucker rats.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Adipose Tissue; Adrenal Glands; Adrenalectomy; Analysis of Variance; Animals; Blood Glucose; Corticosterone; Eating; Hydroxysteroid Dehydrogenases; Hypertrophy; Hypoglycemic Agents; Insulin; Liver; Male; Metformin; Obesity; Omentum; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Weight Gain | 2000 |
The effects of rexinoids and rosiglitazone on body weight and uncoupling protein isoform expression in the Zucker fa/fa rat.
Topics: Adipose Tissue, Brown; Animals; Body Weight; Carrier Proteins; Eating; Ion Channels; Membrane Proteins; Membrane Transport Proteins; Mitochondrial Proteins; Nicotinic Acids; Obesity; Proteins; Rats; Rats, Zucker; Receptors, Retinoic Acid; Retinoid X Receptors; RNA, Messenger; Rosiglitazone; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors; Uncoupling Protein 1; Uncoupling Protein 2; Uncoupling Protein 3; Weight Gain | 2000 |
The hormone resistin links obesity to diabetes.
Topics: 3T3 Cells; Adipocytes; Amino Acid Sequence; Animals; Base Sequence; Chromosomes, Human, Pair 19; Cloning, Molecular; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet; DNA; Female; Gene Expression Regulation; Glucose Intolerance; Hormones; Hormones, Ectopic; Humans; Hypoglycemic Agents; Insulin Antagonists; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred C57BL; Molecular Sequence Data; Nerve Growth Factor; Neutralization Tests; Obesity; Proteins; Resistin; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones | 2001 |
Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents.
Topics: Adipose Tissue; Animals; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Experimental; Disease Models, Animal; Gene Expression; Glucose Tolerance Test; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Liver; Male; Muscle, Skeletal; Nicotinic Acids; Obesity; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; RNA, Messenger; Rosiglitazone; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death.
Topics: Aging; Animals; Blood Glucose; Body Weight; Cell Death; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Hypoglycemic Agents; Insulin; Islets of Langerhans; Male; Obesity; Organ Size; Pancreas; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability.
Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Fasting; Fatty Acids, Nonesterified; Glucose Clamp Technique; Humans; Hyperinsulinism; Hypertriglyceridemia; Hypoglycemic Agents; Infusions, Intravenous; Insulin; Kinetics; Lipid Mobilization; Lipoproteins, VLDL; Liver; Male; Metabolic Clearance Rate; Muscle, Skeletal; Obesity; Oxidation-Reduction; Polyethylene Glycols; Postprandial Period; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Triglycerides | 2001 |
Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists.
Topics: Adipocytes; Animals; Benzophenones; Down-Regulation; Hormones, Ectopic; Hypoglycemic Agents; Intercellular Signaling Peptides and Proteins; Male; Mice; Nerve Growth Factor; Obesity; Proteins; Rats; Receptors, Cytoplasmic and Nuclear; Resistin; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tyrosine | 2001 |
Insulin-sensitizing action of rosiglitazone is enhanced by preventing hyperphagia.
Topics: Animals; Body Weight; Carrier Proteins; Eating; Food Deprivation; Hyperphagia; Hypoglycemic Agents; Hypothalamus; Insulin Resistance; Ion Channels; Leptin; Male; Mitochondrial Proteins; Neuropeptide Y; Obesity; Rats; Rats, Wistar; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Uncoupling Protein 3 | 2001 |
Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones.
Topics: Animals; Chromans; Diabetes Mellitus; Fatty Liver; Gene Expression; Hypoglycemic Agents; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Obesity; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Up-Regulation | 2001 |
Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes.
Topics: 3T3 Cells; Adipose Tissue; Animals; Benzhydryl Compounds; Benzoates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Epoxy Compounds; Fatty Acids; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Leptin; Mice; Mice, Knockout; Nicotinic Acids; Obesity; Receptors, Adrenergic, beta-3; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Rosiglitazone; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats.
Topics: 3T3 Cells; Adipocytes; Adipose Tissue; Administration, Oral; Animals; Blood Glucose; Body Weight; Glucose; Glucose Clamp Technique; Glucose Transporter Type 1; Glucose Transporter Type 4; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Mice; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Obesity; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Thinness | 2001 |
Thiazolidinediones influence plasma steroids of male obese Zucker rats.
Topics: Animals; Blood Glucose; Body Weight; Chromans; Glucose; Hormones; Insulin; Male; Muscle, Skeletal; Obesity; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Heart; Heart Rate; Hypoglycemic Agents; Insulin Resistance; Myocardial Ischemia; Myocardial Reperfusion; Obesity; Organ Size; Perfusion; Rats; Rats, Zucker; Reference Values; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors | 2002 |
Increased lipolysis and decreased leptin production by human omental as compared with subcutaneous preadipocytes.
Topics: Adipocytes; Adult; Aged; Body Mass Index; Cell Differentiation; Female; Glycerol; Humans; Hypoglycemic Agents; Leptin; Lipolysis; Male; Middle Aged; Norepinephrine; Obesity; Omentum; RNA, Messenger; Rosiglitazone; Skin; Thiazoles; Thiazolidinediones; Transcription, Genetic; Tumor Necrosis Factor-alpha | 2002 |
Normalization of skeletal muscle glycogen synthesis and glycolysis in rosiglitazone-treated Zucker fatty rats: an in vivo nuclear magnetic resonance study.
Topics: Animals; Disease Models, Animal; Gluconeogenesis; Glycolysis; Kinetics; Magnetic Resonance Spectroscopy; Models, Biological; Muscle, Skeletal; Obesity; Rats; Rats, Zucker; Reference Values; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
Combination of insulin and thiazolidinedione therapy in massively obese patients with Type 2 diabetes.
Topics: Adult; Aged; Body Mass Index; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Edema; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Obesity; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |